

Wetenschappelijk overzicht IKNL 2022

Wetenschappelijk overzicht IKNL 2022

Auteur
A.M. Kuijpers-Ruurs

Inhoudsopgave

1	Algemeen	5
1.1	Publicaties met impactfactor	5
1.2	Overige publicaties	11
1.3	Proefschriften en promoties	12
2	Borstkanker	13
2.1	Publicaties met impactfactor	13
2.2	Overige publicaties	16
3	Bot-en wekedelentumoren	17
3.1	Publicaties met impactfactor	17
4	Darmkanker	18
4.1	Publicaties met impactfactor	18
4.2	Overige publicaties	21
4.3	Proefschriften en promoties	22
5	Gynaecologische tumoren	23
5.1	Publicaties met impactfactor	23
5.2	Proefschriften en promoties	26
6	Hemato-oncologie	27
6.1	Publicaties met impactfactor	27
6.2	Overige publicaties	29
6.3	Proefschriften en promoties	29
7	Hoofdhalskanker	30
7.1	Publicaties met impactfactor	30
7.2	Overige publicaties	31
8	Huidkanker	32
8.1	Publicaties met impactfactor	32
9	Longkanker	34
9.1	Publicaties met impactfactor	34
10	Neuro-endocriene tumoren	35
10.1	Publicaties met impactfactor	35
11	Neuro-oncologie	36
11.1	Publicaties met impactfactor	36
11.2	Overige publicaties	36
12	Upper GI & HPB	37
12.1	Publicaties met impactfactor	37
12.2	Overige publicaties	40
12.3	Proefschriften en promoties	40
13	Urogenitale kanker	41
13.1	Publicaties met impactfactor	41
13.2	Overige publicaties	43
B1	Impactfactoren tijdschriften	44

1 Algemeen

1.1 Publicaties met impactfactor

Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermipas P, Baumert BG, Hurkmans C, Høyer M, Langendijk JA, Kaidar-Person O, [van der Linden Y](#), Meattini I, Niyazi M, Reynaert N, de Ruyscher D, Tanadini-Lang S, Hoskin P, Poortmans P, Nieder C. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. *Lancet Oncol*. 2022 Oct;23(10):e469-e478. doi: 10.1016/S1470-2045(22)00447-8. Impactfactor: 54,433

Bakker EM, Witkamp FE, Luu KL, van Dongen SI, [Raijmakers NJ](#), [van Roij J](#), van der Heide A, Rietjens JA. Caregiver activation of relatives of patients with advanced cancer. *Eur J Cancer Care (Engl)*. 2022 Jul 16. doi: 10.1111/ecc.13656. Online ahead of print. Impactfactor: 2,328

[Beerda DC](#), Zegers AD, [van Andel ES](#), Becker-Commissaris A, van der Vorst MJ, Tange D, [Duijts SF](#), [Brom L](#). Experiences and perspectives of patients with advanced cancer regarding work resumption and work retention: a qualitative interview study. *Support Care Cancer*. 2022 Dec;30(12):9713-9721. doi: 10.1007/s00520-022-07436-1. Epub 2022 Nov 25. Impactfactor: 3,359

Behroozian T, Fatima S, Finkelstein S, Kanee L, Bonomo P, Wolf JR, Vassiliou V, [van den Hurk C](#), Chow E, Beveridge M. Current quality of life assessment tools may not fully address dermatological adverse events from anti-cancer therapies. *Support Care Cancer*. 2022 Oct 24. doi: 10.1007/s00520-022-07424-5. Online ahead of print. Impactfactor: 3,359

[Boddaert MS](#), [Douma J](#), [Dijxhoorn AQ](#), Héman RA, van der Rijt CC, Teunissen SS, [Huijgens PC](#), Vissers KP. Development of a national quality framework for palliative care in a mixed generalist and specialist care model: A whole-sector approach and a modified Delphi technique. *PLoS One*. 2022 Mar 23;17(3):e0265726. doi: 10.1371/journal.pone.0265726. eCollection 2022. Impactfactor: 3,752

Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, Innos K, Mihor A, Erdmann F, Spix C, Lacour B, Marcos-Gragera R, Murray D, Rossi S; EUROCARE-6 Working Group ([Visser O](#), [Karim-Kos HE](#)). Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. *Lancet Oncol*. 2022 Dec;23(12):1525-1536. doi: 10.1016/S1470-2045(22)00637-4. Epub 2022 Nov 16. Impactfactor: 54,433

Cabasag CJ, Vignat J, Ferlay J, Arndt V, [Lemmens VE](#), [Praagman J](#), Bray F, Soerjomataram I. The preventability of cancer in Europe: a quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020. *Eur J Cancer*. 2022 Oct 4;177:15-24. doi: 10.1016/j.ejca.2022.09.030. Online ahead of print. Impactfactor: 10,002

Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, [Oerlemans S](#), Velikova G, Pinto M, Tomaszewski KA, Aaronson NK, Exall E, Finbow C, Fitzsimmons D, Grant L, Groenvold M, Tolley C, Wheelwright S, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. *Eur J Cancer*. 2023 Jan;178:128-138. doi: 10.1016/j.ejca.2022.10.026. Epub 2022 Nov 1. Impactfactor: 10,002

Coenen P, Zegers AD, de Vreeze N, van der Beek AJ, [Duijts SF](#). 'Nobody can take the stress away from me': a qualitative study on experiences of partners of patients with cancer regarding their work and health. *Disabil Rehabil*. 2022 May 23;1-9. doi: 10.1080/09638288.2022.2074547. Online ahead of print. Impactfactor: 2,439

de Boer AG, de Wind A, Coenen P, van Ommen F, Greidanus MA, Zegers AD, **Duijts SF**, Tamminga SJ. Cancer survivors and adverse work outcomes: associated factors and supportive interventions. *Br Med Bull.* 2022 Nov 12;ldac028. doi: 10.1093/bmb/ldac028. Online ahead of print. Impactfactor: 5,841

de Haan-Du J, Groenier KH, **Wauben-Spaetgens B**, Jalving M, Kleefstra N, Landman GW, de Bock GH. The value of glycemic control prior to cancer diagnosis on all-cause mortality among patients with type 2 diabetes in Dutch primary care. *Cancer Epidemiol Biomarkers Prev.* 2022 Nov 28;EPI-22-0766. doi: 10.1158/1055-9965.EPI-22-0766. Online ahead of print. Impactfactor: 4,090

de Heus E, Duijts SF, van der Zwan JM, Kapiteijn E, Nieveen van Dijkum EJ, van Herpen CM, **Merkx MA**. The gap between rare and common cancers still exists: results from a population-based study in the Netherlands. *Eur J Cancer.* 2022 Apr 11;167:103-111. doi: 10.1016/j.ejca.2022.03.001. Online ahead of print. Impactfactor: 10,002

Dijxhoorn AF, Raijmakers N, van der Linden Y, Leget C, **Brom L**. Clinicians' perceptions of the emotional impact of providing palliative care: a qualitative interview study. *Palliat Support Care.* 2022 Aug 19:1-7. doi: 10.1017/S1478951522000980. Online ahead of print. Impactfactor: 3,733

Ebben KC, Hendriks MP, Markus L, Kos M, De Hingh IH, Oddens JR, Rothbarth J, De Wilt H, Strobbe LJA, Bessems M, Mellema CT, **Siesling S, Verbeek XA**. Using guideline-based clinical decision support in oncological multidisciplinary team meetings: a prospective, multicenter concordance study. *Int J Qual Health Care.* 2022 Mar 19;34(1):mzac007. doi: 10.1093/intqhc/mzac007. Impactfactor: 2,257

Ehrenstein JK, van Zon SK, **Duijts SF**, Stewart RE, Almansa J, Amick BC 3rd, Schagen SB, Bültmann U. Trajectories of cognitive symptoms and associated factors in cancer survivors after return to work: an 18-month longitudinal cohort study. *J Cancer Surviv.* 2022 Mar 21. doi: 10.1007/s11764-022-01190-3. Online ahead of print. Impactfactor: 4,062

Finkelstein S, Kanee L, Behroozian T, Wolf JR, **van den Hurk C**, Chow E, Bonomo P. Comparison of clinical practice guidelines on radiation dermatitis: a narrative review. *Support Care Cancer.* 2022 Jan 24. doi: 10.1007/s00520-022-06829-6. Online ahead of print. Impactfactor: 3,359

Ham L, Fransen HP, van Roij J, van den Borne B, Creemers GJ, Hendriks MP, Kuip E, van Laarhoven HW, van Leeuwen L, van der Padt-Pruijsten A, Smilde T, Stellingwerf M, van Zuylen L, **van de Poll-Franse LV, Raijmakers NH**. Emotional functioning during bereavement after the death of patients with advanced cancer and associated factors. *Psychooncology.* 2022 Sep 12. doi: 10.1002/pon.6031. Online ahead of print. Impactfactor: 3,955

Hermans KE, van den Brandt PA, **Loef C**, Jansen RL, Schouten LJ. Adherence to the World Cancer Research Fund and the American Institute for Cancer Research lifestyle recommendations for cancer prevention and Cancer of Unknown Primary risk. *Clin Nutr.* 2022 Jan 4;41(2):526-535. doi: 10.1016/j.clnu.2021.12.038. Online ahead of print. Impactfactor: 7,643

Hermans KE, Haque S, van den Brandt PA, **Loef C**, Jansen RH, Schouten L. Type 2 diabetes mellitus and cancer of unknown primary risk: results from the Netherlands Cohort Study. *Eur J Cancer Prev.* 2022 Mar 8. doi: 10.1097/CEJ.0000000000000749. Online ahead of print. Impactfactor: 2,164

Hermans KE, van den Brandt PA, **Loef C**, Jansen RL, Schouten LJ. Vegetable and fruit consumption and cancer of unknown primary risk: results from the Netherlands cohort study on diet and cancer. *BMC Cancer.* 2022 Apr 13;22(1):399. doi: 10.1186/s12885-022-09502-7. Impactfactor: 4,638

Hoffstädt HE, Boogaard JA, Tam MC, van Bodegom-Vos L, **Stoppelenburg A, Hartog ID, van der Linden YM**, van der Steen JT. Practice of Supporting Family Caregivers of Patients with Life-Threatening Diseases: A Two-phase Study Among Healthcare Professionals. *Am J Hosp Palliat Care*. 2022 Nov 27;10499091221123006. doi: 10.1177/10499091221123006. Online ahead of print. Impactfactor: 2,090

Janssen SH, van der Meer DJ, **van Eenbergen MC**, Manten-Horst E, van der Graaf WT, Husson O. Short- and long-term impact of cancer on employment and financial outcomes of adolescents and young adults (AYAs): a large population-based case-control registry study in the Netherlands. *ESMO Open*. 2022 Jun 27;7(4):100521. doi: 10.1016/j.esmoop.2022.100521. Online ahead of print. Impactfactor: 6,883

Jones JA, Chavarri-Guerra Y, Corrêa LBC, Dean DR, Epstein JB, Fregnani ER, Lee J, Matsuda Y, Mercadante V, Monsen RE, **Rajmakers NJ**, Saunders D, Soto-Perez-de-Celis E, Sousa MS, Tonkaboni A, Vissink A, Yeoh KS, Davies AN. MASCC/ISOO expert opinion on the management of oral problems in patients with advanced cancer. *Support Care Cancer*. 2022 Jun 18. doi: 10.1007/s00520-022-07211-2. Online ahead of print. Impactfactor: 3,359

Kamphorst B, Rooijackers T, Veugen T, **Cellamare M, Knoors D**. Accurate training of the Cox proportional hazards model on vertically-partitioned data while preserving privacy. *BMC Med Inform Decis Mak*. 2022 Feb 24;22(1):49. doi: 10.1186/s12911-022-01771-3. Impactfactor: 3,298

Klaver KM, **Duijts SF**, Geusgens CA, Aarts MJ, Ponds RW, van der Beek AJ, Schagen SB. Neuropsychological test performance and self-reported cognitive functioning associated with work-related outcomes in occupationally active cancer survivors with cognitive complaints. *J Cancer Surviv*. 2022 Jul 1. doi: 10.1007/s11764-022-01223-x. Online ahead of print. Impactfactor: 4,062

Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, La Vecchia C, Allemani C, Lievens Y, Naredi P, Cufer T, Aggarwal A, Aapro M, Apostolidis K, Baird AM, Cardoso F, Charalambous A, Coleman MP, Costa A, Crul M, Dégi CL, Di Nicolantonio F, Erdem S, Geanta M, Geissler J, Jassem J, Jagielska B, Jonsson B, Kelly D, Kelm O, Kolarova T, Kutluk T, Lewison G, Meunier F, Pelouchova J, Philip T, Price R, Rau B, Rubio IT, Selby P, Južnič Sotlar M, Spurrier-Bernard G, **van Hooft JC**, Vrdoljak E, Westerhuis W, Wojciechowska U, Sullivan R. European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission. *Lancet Oncol*. 2022 Nov 15:S1470-2045(22)00540-X. doi: 10.1016/S1470-2045(22)00540-X. Online ahead of print. Impactfactor: 54,433

Lize N, Rajmakers N, van den Berg M, Emmaneel L, Kok A, Lagendijk M, van Leeuwen-Bouwhuis K, van Lieshout R, **Nagel Z, Beijer S**. Patients with cancer experience high impact of emotional consequences of reduced ability to eat: a cross sectional survey study. *Eur J Cancer Care (Engl)*. 2022 Apr 27. doi: 10.1111/ecc.13595. Online ahead of print. Impactfactor: 2,328

Lugtenberg RT, **van den Hurk CJ**, Smorenburg CH, Mosch L, Houtsma D, Deursen MA, Kaptein AA, Gelderblom H, Kroep JR. Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia - a randomized controlled trial. *Support Care Cancer*. 2022 May 2. doi: 10.1007/s00520-022-07090-7. Online ahead of print. Impactfactor: 3,359

Meijer R, van Hooff M, Papen-Botterhuis NE, Molenaar CJ, Regis M, Timmers T, **van de Poll-Franse LV**, Savelberg HH, Schep G. Estimating VO_{2peak} in 18-90 year-old adults: development and validation of the FitMáx©-Questionnaire. *Int J Gen Med*. 2022 Apr 5;15:3727-3737. doi: 10.2147/IJGM.S355589. eCollection 2022. Impactfactor: 2,145

Olischläger DL, den Boer LX, de Heus E, Brom L, Dona DJS, Klümpen HJ, Stapelfeldt CM, Duijts SF. Rare cancer and return to work: experiences and needs of patients and (health care) professionals. *Disabil Rehabil.* 2022 Jul 18;1-12. doi: 10.1080/09638288.2022.2099589. Online ahead of print. Impactfactor: 2,439

Oosterveld-Vlug MG, Heins MJ, **Boddaert MS**, Engels Y, Heide AV, Onwuteaka-Philipsen BD, Reyners AK, Francke AL. Evaluating quality of care at the end of life and setting best practice performance standards: a population-based observational study using linked routinely collected administrative databases. *BMC Palliat Care.* 2022 Apr 12;21(1):51. doi: 10.1186/s12904-022-00927-2. Impactfactor: 3,113

Oosting SF, van der Veldt AM, Fehrmann RN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJ, den Hartog G, Jalving M, **Westphal TT**, Bhattacharya A, de Wilt F, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CA, Rots NY, van Baarle D, Haanen JB, de Vries EG. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. *Lancet Oncol.* 2022 Apr 25:S1470-2045(22)00203-0. doi: 10.1016/S1470-2045(22)00203-0. Online ahead of print. Impactfactor: 54,433

Oosting SF, van der Veldt AA, Geurts van Kessel CH, Fehrmann RS, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJ, den Hartog G, Jalving M, **Westphal TT**, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MP, Huckriede AL, van Els CA, Rots NY, van Baarle D, Haanen JB, de Vries EG. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. *Lancet Oncol.* 2021 Dec;22(12):1681-1691. doi: 10.1016/S1470-2045(21)00574-X. Epub 2021 Nov 9. Impactfactor: 54,433

Özdemir BC, Oertelt-Prigione S, Adjei AA, Borchmann S, Haanen JB, Letsch A, Mir O, Quaas A, **Verhoeven RH**, Wagner AD. Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. *Ann Oncol.* 2022 Feb;33(2):126-128. doi: 10.1016/j.annonc.2021.11.011. Epub 2022 Jan 17. Impactfactor: 51,769

Raijmakers NJ, van Zuylen L, Fürst CJ. Timely integration of palliative care into cancer care. *Eur J Cancer Care (Engl).* 2022 Nov;31(6):e13764. doi: 10.1111/ecc.13764. Impactfactor: 2,328

Saris LM, **Vlooswijk C**, Kaal SE, Nuver J, Bijlsma RM, van der Hulle T, Kouwenhoven MC, Tromp JM, Lalisang RI, Bos ME, van der Graaf WT, Husson O. A Negative Body Image among Adolescent and Young Adult (AYA) Cancer Survivors: Results from the Population-Based SURVAYA Study. *Cancers (Basel).* 2022 Oct 26;14(21):5243. doi: 10.3390/cancers14215243. Impactfactor: 6,575

Snijders R, Raijmakers NJ, Frouzian A, Kodde A, Kazimier H, Bols F, Zerstegen C, **Brom L**. Trends in Palliative Care Telephone Consultation Support for Health Care Professionals: A Dutch Nationwide Registry between 2004 and 2019. *J Palliat Med.* 2022 Aug 22. doi: 10.1089/jpm.2022.0097. Online ahead of print. Impactfactor: 2,947

Stoevelaar R, Juffermans CC, Roorda IM, de Nijs EJ, Hoornweg J, Cannegieter SC, **van der Linden YM**. A simple risk score list can be used to predict the occurrence of delirium in patients admitted to inpatient hospice care: a medical record study. *Eur J Cancer Care (Engl).* 2022 Jul 15. doi: 10.1111/ecc.13658. Online ahead of print. Impactfactor: 2,328

van Cappellen-van Maldegem SJ, Hoedjes M, Seidell JC, **van de Poil-Franse LV**, Buffart LM, **Mols F, Beijer S**. Self-performed Five Times Sit-To-Stand test at home as (pre-)screening tool for frailty in cancer survivors: Reliability and agreement assessment. *J Clin Nurs.* 2022 Mar 24. doi: 10.1111/jocn.16299. Online ahead of print. Impactfactor: 4,423

van de Graaf DL, Vlooswijk C, Bol N, Krahmer EJ, Bijlsma R, Kaal S, Sleeman SH, van der Graaf WT, Husson O, **van Eenbergen M**. AYAs' online information and eHealth needs: a comparison with healthcare professionals' perceptions. *Cancer Med*. 2022 Jul 25. doi: 10.1002/cam4.5048. Online ahead of print. Impactfactor: 4,711

van de Graaf DL, Mols F, Trompetter HR, van der Lee ML, Schreurs KM, Børøund E, Nes LS, Smeets T. Effectiveness of the online Acceptance and Commitment Therapy intervention "Embrace Pain" for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy: study protocol for a randomized controlled trial. *Trials*. 2022 Aug 9;23(1):642. doi: 10.1186/s13063-022-06592-3. Impactfactor: 2,728

van de Poll-Franse LV, Horevoorts N, Schoormans D, **Beijer S, Ezendam NP**, Husson O, **Oerlemans S**, Schagen SB, Hageman GJ, van Deun K, **van den Hurk CV, van Eenbergen M, Mols F**; Profiles Registry Group. Measuring Clinical, Biological, and Behavioral Variables to Elucidate Trajectories of Patient (Reported) Outcomes: The PROFILES Registry. *J Natl Cancer Inst*. 2022 Feb 24:djac047. doi: 10.1093/jnci/djac047. Online ahead of print. Impactfactor: 11,816

van de Wal D, Janssen SH, van der Meer DJ, **Vlooswijk CC**, Roos DC, Bootsma TI, Fles R, Burgers VW, Husson O. Switching the scope from "how to identify cancer survivors" to "who is participating in cancer survivorship research": a proposal for a new focus. *Cancer*. 2022 Feb 8. doi: 10.1002/cncr.34130. Online ahead of print. Impactfactor: 6,921

van den Hurk CJ, Sonis ST, Epstein JB. A common infrastructure for real-world patient-reported symptoms: one size fits many. *Support Care Cancer*. 2022 Jul 28. doi: 10.1007/s00520-022-07295-w. Online ahead of print. Impactfactor: 3,359

van den Hurk CJ, Mols F, Eicher M, Chan RJ, Becker A, **Geleijnse G**, Walraven I, Coolbrandt A, Lustberg M, Velikova G, Charalambous A, Koczwara B, Howell D, Basch EM, **van de Poll-Franse LV**. A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring. *Curr Oncol*. 2022 Jun 17;29(6):4370-4385. doi: 10.3390/curroncol29060349. Impactfactor: 3,109

van der Padt-Pruijsten A, Oostergo T, Leys MB, **van der Rijt CC**, van der Heide A. Hospitalisations of patients with cancer in the last stage of life. Reason to improve advance care planning? *Eur J Cancer Care (Engl)*. 2022 Sep 29:e13720. doi: 10.1111/ecc.13720. Online ahead of print. Impactfactor: 2,328

van der Stap L, van Haften MF, van Marrewijk EF, de Heij AH, Jansen PL, Burgers JM, **Sieswerda MS**, Los RK, Reyners AL, **van der Linden YM**. The feasibility of a Bayesian network model to assess the probability of simultaneous symptoms in patients with advanced cancer. *Sci Rep*. 2022 Dec 24;12(1):22295. doi: 10.1038/s41598-022-26342-4. Impactfactor: 4,997

van der Strate I, Kazemzadeh F, Nagtegaal ID, Robbrecht D, van de Wouw A, **Padilla CS, Duijts SF**, Esteller M, Greco FA, Pavlidis N, Qaseem A, Snaebjornsson P, van Zanten SV, **Loef C**. International consensus on the initial diagnostic workup of cancer of unknown primary. *Crit Rev Oncol Hematol*. 2023 Jan;181:103868. doi: 10.1016/j.critrevonc.2022.103868. Epub 2022 Nov 23. Impactfactor: 6,625

van Dongen J, de Heus E, Eickholt L, Schrieks M, Zantingh I, Brouwer OR, Oonk MH, Grotenhuis BA, **Ezendam NP, Duijts SF**. Challenges and controversies patients and (health care) professionals experience in managing vaginal, vulvar, penile or anal cancer: The SILENCE study. *Eur J Cancer Care (Engl)*. 2022 Aug 8:e13676. doi: 10.1111/ecc.13676. Online ahead of print. Impactfactor: 2,328

van Roij J, Raijmakers NJ, Kloover J, Kuip E, Smilde T, van der Velden LA, Rodin G, **van de Poll-Franse LV**. Dyadic coping and its association with emotional functioning in couples confronted with advanced cancer: Results of the multicenter observational eQuiPe study. *Psychooncology*. 2022 May 18. doi: 10.1002/pon.5961. Online ahead of print. Impactfactor: 3,955

van Roij J, Raijmakers N, Ham L, van den Beuken-van Everdingen M, van den Borne B, Creemers GJ, Cornelis Hunting J, Kuip E, van Leeuwen L, van Laarhoven H, Mandigers C, Nieboer P, van der Velden LA, Zuylen LV, Gelissen J, **Zijlstra M, Brom L, Franssen HP, van de Poll-Franse LV**; eQuiPe study group. Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe). *Eur J Cancer*. 2022 Feb 27;165:125-135. doi: 10.1016/j.ejca.2022.01.039. Online ahead of print. Impactfactor: 10,002

van Roij J, Raijmakers N, Johnsen AT, Hansen MB, Thijs-Visser M, **van de Poll-Franse LV**. Sexual health and closeness in couples coping with advanced cancer: Results of a multicenter observational study (eQuiPe). *Palliat Med*. 2022 Feb 20:2692163221074541. doi: 10.1177/02692163221074541. Online ahead of print. Impactfactor: 5,713

Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, **van de Poll-Franse LV**, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. *Ann Oncol*. 2022 Aug 10:S0923-7534(22)03792-9. doi: 10.1016/j.annonc.2022.07.1941. Online ahead of print. Impactfactor: 51,769

Versluis A, van Alphen K, Dercksen W, de Haas H, **van den Hurk C**, Kaptein AA. "Dear hair loss"-illness perceptions of female patients with chemotherapy-induced alopecia. *Support Care Cancer*. 2022 Jan 20. doi: 10.1007/s00520-021-06748-y. Online ahead of print. Impactfactor: 3,359

Versluis A, Alphen KV, Dercksen W, Haas H, Kaptein AA, **Hurk CV**. Looking bad: Female patients drawing their representation of chemotherapy-induced alopecia. *J Health Psychol*. 2022 Feb 25:13591053221075503. doi: 10.1177/13591053221075503. Online ahead of print. Impactfactor: 3,789

Versteegh M, van der Helm I, Mokri H, **Oerlemans S**, Blommestein H, van Baal P. Estimating Quality of Life Decrements in Oncology Using Time to Death. *Value Health*. 2022 Jul 5:S1098-3015(22)02038-1. doi: 10.1016/j.jval.2022.06.002. Online ahead of print. Impactfactor: 5,156

Vlooswijk C, Poll-Franse LV, Janssen SH, **Derksen E**, Reuvers MJ, Bijlsma R, **Kaal SE**, Kerst JM, Tromp JM, Bos ME, Hulle TV, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study. *Curr Oncol*. 2022 Jul 29;29(8):5407-5425. doi: 10.3390/curroncol29080428. Impactfactor: 3,109

Voets MM, Veltman J, Slump CH, **Siesling S**, Koffijberg H. Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah. *Value Health*. 2022 Mar;25(3):340-349. doi: 10.1016/j.jval.2021.11.1362. Impactfactor: 5,156

Vromans RD, Hommes S, Clouth FJ, Lo-Fo-Wong DN, **Verbeek XA, van de Poll-Franse LV**, Pauws S, Krahmer E. Need for numbers: assessing cancer survivors' needs for personalized and generic statistical information. *BMC Med Inform Decis Mak*. 2022 Oct 5;22(1):260. doi: 10.1186/s12911-022-02005-2. Impactfactor: 3,298

Walraven JE, [van der Hel OL](#), van der Hoeven JJ, [Lemmens VE](#), [Verhoeven RH](#), Desar IM. Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review. *BMC Health Serv Res*. 2022 Jun 27;22(1):829. doi: 10.1186/s12913-022-08112-0. Impactfactor: 2,908

Walraven JE, van der Meulen R, van der Hoeven JJ, [Lemmens VE](#), [Verhoeven RH](#), Hesselink G, Desar IM. Preparing tomorrow's medical specialists for participating in oncological multidisciplinary team meetings: perceived barriers, facilitators and training needs. *BMC Med Educ*. 2022 Jun 27;22(1):502. doi: 10.1186/s12909-022-03570-w. Impactfactor: 3,263

Zegers AD, Coenen P, Bültmann U, van Hummel R, van der Beek AJ, [Duijts SF](#). Tailoring work participation support for cancer survivors using the stages of change: perspectives of (health care) professionals and survivors. *J Cancer Surviv*. 2022 Mar 11. doi: 10.1007/s11764-022-01196-x. Online ahead of print. Impactfactor: 4,062

Zegers AD, [van Andel ES](#), Beerda DC, Dona DJ, Aukema EJ, [Brom L](#), [Duijts SF](#). Work resumption and retention in patients with advanced cancer: Experiences and perspectives of general and occupational health care professionals. *Eur J Cancer Care (Engl)*. 2022 Sep 27:e13714. doi: 10.1111/ecc.13714. Online ahead of print. Impactfactor: 2,328

Zeraatkar D, Cooper MA, Agarwal A, [Vernooij RW](#), Leung G, Loniewski K, Dookie JE, Ahmed MM, Hong BY, Hong C, Hong P, Couban R, Agoritsas T, Busse JW. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies. *BMJ Open*. 2022 Aug 4;12(8):e054282. doi: 10.1136/bmjopen-2021-054282. Impactfactor: 3,007

1.2 Overige publicaties

Albers EA, Fraterman I, Walraven I, Wilthagen E, Schagen SB, van der Ploeg IM, Wouters MW, [van de Poll-Franse LV](#), de Ligt KM. Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy. *J Patient Rep Outcomes*. 2022 Mar 3;6(1):18. doi: 10.1186/s41687-022-00424-3.

Beuken MJ, Kanera IM, [Ezendam NM](#), Braun S, Zoet M. Identification and Potential Use of Clusters of Patients With Colorectal Cancer and Patients With Prostate Cancer in Clinical Practice: explorative Mixed Methods Study. *JMIR Cancer*. 2022 Dec 27;8(4):e42908. doi: 10.2196/42908.

Nwosu AC, McGlinchey T, Sanders J, Stanley S, Palfrey J, [Lubbers P](#), Chapman L, Finucane A, Mason S. Identification of Digital Health Priorities for Palliative Care Research: Modified Delphi Study. *JMIR Aging*. 2022 Mar 21;5(1):e32075. doi: 10.2196/32075.

Pijls BG, Jolani S, Atherley A, Dijkstra JIR, Franssen GHL, Hendriks S, Yi-Wen Yu E, Zalpuri S, [Richters A](#), Zeegers MP. Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients. *F1000Res*. 2022 Jan 5;11:5. doi: 10.12688/f1000research.74645.1. eCollection 2022.

Smits D, [van Beusekom B](#), [Martin F](#), Veen L, [Geleijnse G](#), [Moncada-Torres A](#). An improved infrastructure for privacy-preserving analysis of patient data. *Stud Health Technol Inform*. 2022 Jun 29;295:144-147. doi: 10.3233/SHTI220682.

[van Eenbergen MC](#), Vromans RD, Tick LW, Vreugdenhil G, Krahmer EJ, [Mols F](#), [van de Poll-Franse LV](#). Comparing Survivors of Cancer in Population-Based Samples With Those in Online Cancer Communities: Cross-sectional Questionnaire Study. *JMIR Cancer*. 2022 Mar 8;8(1):e19379. doi: 10.2196/19379.

[van Ham CR](#), Burgers VW, Sleeman SH, Dickhout A, Harthoorn NC, Manten-Horst E, [van Eenbergen MC](#), Husson O. A qualitative study on the involvement of adolescents and young adults (AYAs) with cancer during multiple research phases: "plan, structure, and discuss". *Res Involv Engagem*. 2022 Jul 8;8(1):30. doi: 10.1186/s40900-022-00362-w.

1.3 Proefschriften en promoties

van Roij J. In it together: a dyadic approach to care experiences and quality of life of patients with advanced cancer and their loved ones. Tilburg: Tilburg University; 22 mei 2022. Promotor: **LV van de Poll-Franse**. Copromotor: **NJ Raijmakers**.

van Roij J. Communicating personalized risks to patients with cancer: a multi-method approach. Tilburg: Tilburg University; 8 juli 2022. Promotores: EJ Krahmer, **LV van de Poll-Franse**, SC Pauw.

2 Borstkanker

2.1 Publicaties met impactfactor

Akdeniz D, Kramer I, van Deurzen CH, Heemskerk-Gerritsen BA, Schaapveld M, Westenend PJ, **Voogd AC**, Jager A, Steyerberg EW, Sleijfer S, Schmidt MK, Hooning MJ. Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: results from a nationwide cohort. *Cancer Med*. 2022 Sep 20. doi: 10.1002/cam4.5235. Online ahead of print. Impactfactor: 4,711

Ankersmid JW, Spronk PE, Zeillemaker AM, **Siesling S**. Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty. *Breast Cancer Res Treat*. 2022 Mar 13. doi: 10.1007/s10549-022-06549-9. Online ahead of print. Impactfactor: 4,624

Ankersmid JW, Drossaert CH, van Riet YE, Strobbe LJ, **Siesling S**; Santeon VBHC Breast Cancer Group. Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance. *J Cancer Surviv*. 2022 Feb 4. doi: 10.1007/s11764-022-01178-z. Online ahead of print. Impactfactor: 4,062

Ankersmid JW, Lansink Rotgerink FK, Strobbe LJ, van Uden-Kraan CF, **Siesling S**, Drossaert CH. Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors. *Breast Cancer Res Treat*. 2022 Jul 30. doi: 10.1007/s10549-022-06684-3. Online ahead of print. Impactfactor: 4,624

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, **Siesling S**, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*. 2022 Sep 2;66:15-23. doi: 10.1016/j.breast.2022.08.010. Online ahead of print. Impactfactor: 4,254

Beenhakker L, Witteveen A, Wijlens KA, Siemerink EJ, van der Lee ML, Bode C, **Siesling S**, Vollenbroek-Hutten MM. Patient preference attributes in eHealth interventions for cancer-related fatigue: a scoping review. *Eur J Cancer Care (Engl)*. 2022 Nov;31(6):e13754. doi: 10.1111/ecc.13754. Epub 2022 Nov 16. Impactfactor: 2,328

de Boer AZ, Bastiaannet E, Schetelig J, de Glas NA, Manevksi D, Putter H, Liefers GJ, **de Munck L**, Portielje JE, de Wreede LC. Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models. *Eur J Cancer*. 2022 Oct;174:212-220. doi: 10.1016/j.ejca.2022.07.029. Epub 2022 Sep 1. Impactfactor: 10,002

de Jong VM, Wang Y, ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CH, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, **Voogd AC**, Loi S, Michiels S, Sonke GS, van der Wall E, **Siesling S**, van Diest PJ, Schmidt MK, Kok M, Dackus GM, Salgado R, Linn SC. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. *J Clin Oncol*. 2022 Mar 30;JCO2101536. doi: 10.1200/JCO.21.01536. Online ahead of print. Impactfactor: 50,739

de Ligt KM, **de Rooij BH**, Walraven I, Heins MJ, **Verloop J**, **Siesling S**, Korevaar JC, **van de Poll-Franse LV**. Varying severities of symptoms underline the relevance of personalized follow-up care in breast cancer survivors: latent class cluster analyses in a cross-sectional cohort. *Support Care Cancer*. 2022 Jun 21. doi: 10.1007/s00520-022-07229-6. Online ahead of print. Impactfactor: 3,359

de Rooij BH, Ramsey I, **Clouth FJ**, Corsini N, Heyworth JS, Lynch BM, Vallance JK, Boyle T. The association of circadian parameters and the clustering of fatigue, depression, and sleep problems in breast cancer survivors: a latent class analysis. *J Cancer Surviv.* 2022 Mar 23. doi: 10.1007/s11764-022-01189-w. Online ahead of print. Impactfactor: 4,062

de Wild SR, **de Munck L**, Simons JM, **Verloop J**, van Dalen T, Elkhuizen PH, Houben RM, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PM, Strobbe LJA, Wesseling J, **Voogd AC**, Boersma LJ. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. *Lancet Oncol.* 2022 Aug 8:S1470-2045(22)00482-X. doi: 10.1016/S1470-2045(22)00482-X. Online ahead of print. Impactfactor: 54,433

Draeger T, Voelkel V, **Schreuder K**, Veltman J, Dassen A, Strobbe L, Heijmans HJ, Koelemij R, Groothuis-Oudshoorn CG, **Siesling S**. Adherence to the Dutch Breast Cancer Guidelines for Surveillance in Breast Cancer Survivors: Real-World Data from a Pooled Multicenter Analysis. *Oncologist.* 2022 Aug 13:oyac126. doi: 10.1093/oncolo/oyac126. Online ahead of print. Impactfactor: 5,837

Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJ, van den Bongard DH, Strobbe LJ, Mureau MA, Lobbes MB, Westenend PJ, Koppert LB, Jager A, Siemerink EJ, Wesseling J, Verkooijen HM, Vrancken Peeters MT, Smidt ML, Tjan-Heijnen VC, **Siesling S**; NABON-COVID-19 Consortium; COVID and Cancer Care-NL Consortium. Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. *Breast Cancer Res Treat.* 2022 Nov 5. doi: 10.1007/s10549-022-06732-y. Online ahead of print. Impactfactor: 4,624

Eijkelboom AH, de Munck L, de Vries M, Francken AB, Hendriks MP, Strobbe L, Witteveen A, **van Maaren MC, Siesling S**. Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis. *Breast Cancer Res Treat.* 2022 Oct 31. doi: 10.1007/s10549-022-06757-3. Online ahead of print. Impactfactor: 4,624

Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PD, **Siesling S**, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~200,000 patients. *Breast Cancer Res.* 2022 Nov 22;24(1):82. doi: 10.1186/s13058-022-01579-z. Impactfactor: 8,408

Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PD, **Siesling S**, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~200,000 patients. *Breast Cancer Res.* 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3. Impactfactor: 8,408

Gooijer SA, Folkersma C, van Steenhoven JE, de Kort J, **Siesling S**, Volders J, van Dalen T. Long-Term Outcome of Sustained Endocrine Monotherapy for Elderly Breast Cancer Patients. *Ann Surg Oncol.* 2022 Nov 3. doi: 10.1245/s10434-022-12662-2. Online ahead of print. Impactfactor: 4,339

Hackert MQ, Ankersmid JW, Engels N, Prick JC, Teerenstra S, **Siesling S**, Drossaert CH, Strobbe LJ, van Riet YE, van den Dorpel RM, Bos WJ, van der Nat PB, van den Berg-Vos RM, van Schaik SM, Garvelink MM, van der Wees PJ, van Uden-Kraan CF; Santeon VBHC breast cancer, stroke and chronic kidney disease group. Effectiveness and implementation of SHared decision-making supported by OUTcome information among patients with breast cancer, stroke and advanced kidney disease: SHOUT study protocol of multiple interrupted time series. *BMJ Open*. 2022 Aug 1;12(8):e055324. doi: 10.1136/bmjopen-2021-055324.

Impactfactor: 3,007

Heins MJ, **de Ligt KM**, **Verloop J**, **Siesling S**, Korevaar JC. Opportunities and obstacles in linking large health care registries: the primary secondary cancer care registry - breast cancer. *BMC Med Res Methodol*. 2022 Apr 27;22(1):124. doi: 10.1186/s12874-022-01601-0.

Impactfactor: 4,614

Hueting TA, **van Maaren MC**, **Hendriks MP**, Koffijberg H, **Siesling S**. The majority of 922 prediction models supporting breast cancer decision-making are at high risk of bias. *J Clin Epidemiol*. 2022 Dec;152:238-247. doi: 10.1016/j.jclinepi.2022.10.016. Epub 2022 Oct 27.

Impactfactor: 7,407

Keymeulen KB, Geurts SM, Kooreman LF, Duijm LE, Engelen S, Vanwetswinkel S, Luiten E, **Siesling S**, **Voogd AC**, Tjan-Heijnen VC. Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study. *Eur Radiol*. 2022 Sep 30. doi: 10.1007/s00330-022-09115-5. Online ahead of print.

Impactfactor: 7,034

Koevoets EW, Schagen SB, de Ruiter MB, Geerlings MI, Witlox L, van der Wall E, Stuiver MM, Sonke GS, **Velthuis MJ**, Jobsen JJ, Menke-Pluijmers MB, Göker E, van der Pol CC, Bos ME, Tick LW, van Holsteijn NA, van der Palen J, May AM, Monninkhof EM; PAM study group. Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study). *Breast Cancer Res*. 2022 May 26;24(1):36. doi: 10.1186/s13058-022-01530-2.

Impactfactor: 8,408

Koevoets EW, Geerlings MI, Monninkhof EM, Mandl R, Witlox L, van der Wall E, Stuiver MM, Sonke GS, **Velthuis MJ**, Jobsen JJ, van der Palen J, Bos ME, Göker E, Menke-Pluijmers MB, Sommeijer DW, May AM; PAM study group, de Ruiter MB, Schagen SB. Effect of physical exercise on the hippocampus and global grey matter volume in breast cancer patients: A randomized controlled trial (PAM study). *Neuroimage Clin*. 2022 Dec 14;37:103292. doi: 10.1016/j.nicl.2022.103292. Online ahead of print.

Impactfactor: 4,891

Meurs CJ, van Rosmalen J, Menke-Pluijmers MB, **Siesling S**, Westenend PJ. Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model. *Ann Surg Oncol*. 2022 Dec 10. doi: 10.1245/s10434-022-12900-7. Online ahead of print.

Impactfactor: 4,339

Meurs CJ, Til JA, Menke-Pluijmers MB, Vet S, **Siesling S**, Westenend PJ. Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ. *PLoS One*. 2022 Jun 6;17(6):e0269551. doi: 10.1371/journal.pone.0269551. eCollection 2022.

Impactfactor: 3,752

Neven A, **van Maaren MC**, **Schreuder K**, **Kranse R**, Struikmans H, Poortmans PM, Bartelink H, Collette L, Liu L, **Siesling S**. Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands Cancer Registry. *J Clin Epidemiol*. 2022 Apr 15:S0895-4356(22)00097-X. doi: 10.1016/j.jclinepi.2022.04.014. Online ahead of print.

Impactfactor: 7,407

Poelhekkem K, Greuter MJ, **de Munck L**, **Siesling S**, Brokken FB, de Bock GH. Long-term effects of the interruption of the Dutch breast cancer screening program due to COVID-19: a modelling study. *Prev Med*. 2022 Dec 6;166:107376. doi: 10.1016/j.ypmed.2022.107376. Online ahead of print.

Impactfactor: 4,637

Ragusi MA, van der Velden BH, **van Maaren MC**, van der Wall E, van Gils CH, Pijnappel RM, Gilhuijs KG, Elias SG. Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA. *Breast Cancer Res Treat.* 2022 Mar 3. doi: 10.1007/s10549-022-06550-2. Online ahead of print. Impactfactor: 4,624

Snoek JA, Nagtegaal ID, **Siesling S**, van den Broek E, van Slooten HJ, Hugen N. The impact of standardized structured reporting of pathology reports for breast cancer care. *Breast.* 2022 Oct 21;66:178-182. doi: 10.1016/j.breast.2022.10.011. Online ahead of print. Impactfactor: 4,254

Suelmann BB, Bakhuis CFJ, van Dooijeweert C, **Verloop J**, Zweemer R, Linn S, van der Wall E, van Diest PJ. Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation. *Breast Cancer Res Treat.* 2022 Jan 18. doi: 10.1007/s10549-021-06471-6. Impactfactor: 4,624

van der Schors W, Kemp R, **van Hove J**, Tjan-Heijnen V, Maduro J, Vrancken Peeters MJ, **Siesling S**, Varkevisser M. Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study. *BMJ Open.* 2022 Apr 26;12(4):e057301. doi: 10.1136/bmjopen-2021-057301. Impactfactor: 3,007

van der Voort A, Liefwaard MC, van Ramshorst MS, van Werkhoven E, Sanders J, Wesseling J, Scholten A, Vrancken Peeters MJ, **de Munck L**, **Siesling S**, Sonke GS. Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. *Breast.* 2022 Jul 13;65:110-115. doi: 10.1016/j.breast.2022.07.005. Online ahead of print. Impactfactor: 4,254

van Maaren MC, Rachet B, Sonke GS, Mauguen A, Rondeau V, **Siesling S**, Belot A. Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands. *Cancer Epidemiol.* 2022 Feb 5;77:102118. doi: 10.1016/j.canep.2022.102118. Online ahead of print. Impactfactor: 2,89

van Steenhoven JE, **van Maaren MC**, Verreck EE, Schipper RJ, Nieuwenhuijzen GA, Kuijper A, **Siesling S**, van Dalen T. Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: innovative hospitals are early adopters of a de-escalating approach. *Int J Cancer.* 2022 Dec 15. doi: 10.1002/ijc.34400. Online ahead of print. Impactfactor: 7,316

Voelkel V, Draeger T, van Mossel S, **Siesling S**, Koffijberg H. The value of time-dependent risk predictions in a screening context - a comprehensive simulation analysis validated on German cancer registry data. *BMC Med Res Methodol.* 2022 Sep 10;22(1):239. doi: 10.1186/s12874-022-01718-2. Impactfactor: 4,614

2.2 Overige publicaties

Ankersmid JW, **Siesling S**, Strobbe LJ, Meulepas JM, van Riet YE, Engels N, Prick JC, The R, Takahashi A, Velting M, van Uden-Kraan CF, Drossaert CH. Supporting Shared Decision-making About Surveillance After Breast Cancer With Personalized Recurrence Risk Calculations: Development of a Patient Decision Aid Using the International Patient Decision AIDS Standards Development Process in Combination With a Mixed Methods Design. *JMIR Cancer.* 2022 Nov 14;8(4):e38088. doi: 10.2196/38088.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Behroozian T, Navarro I, Hoskin P, Johnstone C, Recht A, Menten J, Oldenburger E, [van der Linden Y](#), van der Velden JM, Nguyen QN, Simone CB, Johnstone P, Lutz S, Milton L, Andratschke N, Willmann J, Kazmierska J, Spalek M, Chow E, Raman S. [Update on the systematic review/meta-analysis of uncomplicated bone metastases treated with external beam radiation](#). *Radiother Oncol*. 2022 Jul 15:S0167-8140(22)04206-2. doi: 10.1016/j.radonc.2022.07.010. Online ahead of print.

Impactfactor: 6,901

Eggermont F, [van der Linden Y](#), Verdonschot N, Dierselhuis E, Ligthert S, Bitter T, Westhoff P, Tanck E. [A Patient-Specific Fracture Risk Assessment Tool for Femoral Bone Metastases: Using the Bone Strength \(BOS\) Score in Clinical Practice](#). *Cancers (Basel)*. 2022 Nov 29;14(23):5904. doi: 10.3390/cancers14235904.

Impactfactor: 6,575

Goedhart LM, [Ho VK](#), Ploegmakers JJ, van der Geest IC, van de Sande MA, Bramer JA, Stevens M, Jutte PC. [Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment](#). *J Bone Oncol*. 2022 Dec 9;38:100466. doi: 10.1016/j.jbo.2022.100466. eCollection 2023 Feb.

Impactfactor: 4,491

Oldenburger E, Brown S, Willmann J, [van der Velden JM](#), Spalek M, [van der Linden YM](#), Kazmierska J, Menten J, Andratschke N, Hoskin P. [ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases](#). *Radiother Oncol*. 2022 Jun 7:S0167-8140(22)04147-0. doi: 10.1016/j.radonc.2022.06.002. Online ahead of print.

Impactfactor: 6,901

Sas A, Tanck E, Wafa H, [van der Linden Y](#), Sermon A, van Lenthe GH. [Fracture risk assessment and evaluation of femoroplasty in metastatic proximal femurs: an in vivo CT-based finite element study](#). *J Orthop Res*. 2022 Apr 2. doi: 10.1002/jor.25331. Online ahead of print.

Impactfactor: 3,103

van der Horst CA, Bongers SL, Versleijen-Jonkers YM, [Ho VK](#), Braam PM, Flucke UE, de Wilt JH, Desar IM. [Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study](#). *Cancers (Basel)*. 2022 Feb 22;14(5):1102. doi: 10.3390/cancers14051102.

Impactfactor: 6,575

4 Darmkanker

4.1 Publicaties met impactfactor

Arron MN, Greijdanus NG, Bastiaans S, **Vissers PA**, **Verhoeven RH**, ten Broek RP, Verheul HM, Tanis PJ, van Goor H, de Wilt JH. Long-term oncological outcomes after colorectal anastomotic leakag: a retrospective Dutch population based study. *Ann Surg*. 2022 Aug 5. doi: 10.1097/SLA.0000000000005647. Online ahead of print. Impactfactor: 13,787

Bolhuis K, Wensink GE, **Elferink MA**, Bond MJ, **Dijksterhuis WP**, Fijneman RJ, Kranenburg OW, Rinkes IH, Koopman M, Swijnenburg RJ, **Vink GR**, Hagendoorn J, Punt CJ, Elias SG, Roodhart JM. External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. *Cancers (Basel)*. 2022 May 10;14(10):2356. doi: 10.3390/cancers14102356. Impactfactor: 6,575

Bond MJ, Hamers PA, **Vink GR**, van Grevenstein WM, Laclé MM, van Smeden M, Koopman M, Roodhart JM, Punt CJ, May AM. External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage I-III colon cancer in a Dutch population. *Acta Oncol*. 2022 Mar 7:1-6. doi: 10.1080/0284186X.2022.2044514. Online ahead of print. Impactfactor: 4,311

Bonhof CS, van de Poll-Franse LV, de Hingh IH, Vreugdenhil G, **Mols F**. Mindfulness is associated with severity of peripheral neuropathy and related patient-reported outcomes among colorectal cancer patients. *Support Care Cancer*. 2022 Aug 28. doi: 10.1007/s00520-022-07340-8. Online ahead of print. Impactfactor: 3,359

Bonhof CS, van de Graaf DL, Wasowicz DK, Vreugdenhil G, **Mols F**. Symptoms of pre-treatment anxiety are associated with the development of chronic peripheral neuropathy among colorectal cancer patients. *Support Care Cancer*. 2022 Mar 18. doi: 10.1007/s00520-022-06971-1. Online ahead of print. Impactfactor: 3,359

Cardoso R, Guo F, Heisser T, de Schutter H, van Damme N, Nilbert MC, Tybjerg AJ, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszekiewicz M, Delafosse P, Poncet F, Walsh PM, Senore C, Rosso S, **Lemmens VE**, **Elferink MA**, Tomšič S, Žagar T, Lopez de Munain Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Sánchez-Gil A, Chirlaque MD, Hoffmeister M, Brenner H. Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study. *Lancet Gastroenterol Hepatol*. 2022 May 10:S2468-1253(22)00084-X. doi: 10.1016/S2468-1253(22)00084-X. Online ahead of print. Impactfactor: 45,042

de Nes LC, Heil TC, **Verhoeven RH**, **Lemmens VE**, Rutten HJ, de Wilt JH, **Vissers PA**. Impact of age on multimodality treatment and survival in locally advanced rectal cancer patients. *Cancers (Basel)*. 2022 May 31;14(11):2741. doi: 10.3390/cancers14112741. Impactfactor: 6,575

de Nes LC, Hannink G, 't Lam-Boer J, Hugen N, **Verhoeven RH**, de Wilt JH; Dutch Colorectal Audit Group. Postoperative mortality risk assessment in colorectal cancer: development and validation of a clinical prediction model using data from the Dutch ColoRectal Audit. *BJS Open*. 2022 Mar 8;6(2):zrac014. doi: 10.1093/bjsopen/zrac014. Impactfactor: 3,875

Driehuis E, de Heus E, Schrieks M, Engelen V, Buffart TE, **Vink GR**, **Duijts SF**. Quality of life of patients with rare cancer: a comparison with patients with colorectal cancer and the association with disease trajectory-related factors. *J Cancer Surviv*. 2022 Dec 31. doi: 10.1007/s11764-022-01324-7. Online ahead of print. Impactfactor: 4,062

Hamers PA, Wensink GE, van Smeden M, **Vink GR**, Smabers LP, Lunenberg RA, Lacleé MM, Koopman M, May AM, Roodhart JM. External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice. *Cancers* (Basel). 2022 Oct 18;14(20):5094. doi: 10.3390/cancers14205094. Impactfactor: 6,575

Hamers PA, **Vink GR**, **Elferink MA**, Stellato RK, **Dijksterhuis WP**, Punt CJ, Koopman M, May AM; QUALITAS study group. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). *Clin Colorectal Cancer*. 2022 Mar 24:S1533-0028(22)00037-8. doi: 10.1016/j.clcc.2022.03.002. Online ahead of print. Impactfactor: 4,035

Hinnen C, **Mols F**. Fluctuations in core depressive symptoms in colorectal cancer patients. A prospective, population-based PROFILES-registry study. *Psychol Health*. 2022 Dec 13:1-17. doi: 10.1080/08870446.2022.2155670. Online ahead of print. Impactfactor: 3,358

Krul MF, **Elferink MA**, Kok NF, Dekker E, Lansdorp-Vogelaar I, Meijer GA, Nagtegaal ID, Breekveldt EC, Ruers TJ, van Leerdam ME, Kuhlmann KF. Initial impact of national CRC screening on incidence and advanced colorectal cancer. *Clin Gastroenterol Hepatol*. 2022 Sep 15:S1542-3565(22)00877-1. doi: 10.1016/j.cgh.2022.08.046. Online ahead of print. Impactfactor: 13,576

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Kuiper MJ, Kuipers EJ, Herings RM. Risk of heart failure among colon and rectal cancer survivors: a population-based case-control study. *ESC Heart Fail*. 2022 Apr 22. doi: 10.1002/ehf2.13923. Online ahead of print. Impactfactor: 3,612

Lurvink RJ, Rijken A, Bakkers C, **Lemmens VE**, de Reuver PR, Tuynman JB, Kok NF, Nienhuijs SW, **van Erning FN**, **de Hingh IH**. The impact of an open or laparoscopic approach on the development of metachronous peritoneal metastases after primary resection of colorectal cancer: results from a population-based cohort study. *Surg Endosc*. 2022 Jan 20. doi: 10.1007/s00464-022-09041-z. Online ahead of print. Impactfactor: 3,453

Meijer J, **Elferink MA**, **van Hoes JC**, Buijsen J, **van Erning FN**, Nagtegaal ID, Tanis PJ, **Vink GR**, Wumkes ML, **de Hingh IH**, **Siesling S**; On-behalf-of-the-COVID-and-Cancer-NL Consortium. Impact of the COVID-19 Pandemic on Colorectal Cancer Care in the Netherlands: A Population-based Study. *Clin Colorectal Cancer*. 2022 Mar 3:S1533-0028(22)00034-2. doi: 10.1016/j.clcc.2022.02.005. Online ahead of print. Impactfactor: 4,035

Meijer J, **Elferink MA**, **Vink GR**, **Sijtsma FP**, Buijsen J, Nagtegaal ID, Tanis PJ, Wumkes ML, **de Hingh IH**, **Siesling S**; COVID and Cancer-NL Consortium. Limited impact of the COVID-19 pandemic on colorectal cancer care in the Netherlands in 2020. *Int J Colorectal Dis*. 2022 Aug 19:1-8. doi: 10.1007/s00384-022-04209-4. Online ahead of print. Impactfactor: 2,796

Meyer YM, Olthof PB, Grünhagen DJ, Swijnenburg RJ, **Elferink MA**, Verhoef C. Interregional practice variations in the use of local therapy for synchronous colorectal liver metastases in the Netherlands. *HPB* (Oxford). 2022 Apr 19:S1365-182X(22)00101-0. doi: 10.1016/j.hpb.2022.04.006. Online ahead of print. Impactfactor: 3,842

Punt CJ, Kwakman JJ, **Mol L**; PLCRC working group (**Vink GR**). Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2022 Mar 2:S1533-0028(22)00027-5. doi: 10.1016/j.clcc.2022.02.004. Online ahead of print. Impactfactor: 4,035

Révész D, van Kuijk SM, **Mols F**, van Duijnhoven FJ, Winkels RM, Kant I, van den Brandt PA, Smits LJ, Breukink SO, Kampman E, **Beijer S**, Weijenberg MP, Bours MJ. External validation and updating of prediction models for estimating the 1-year risk of low health-related quality of life in colorectal cancer survivors. *J Clin Epidemiol*. 2022 Oct 8:S0895-4356(22)00240-2. doi: 10.1016/j.jclinepi.2022.09.019. Online ahead of print. Impactfactor: 7,407

Révész D, Bours MJ, Weijenberg MP, **Mols F**. Longitudinal Associations of Former and Current Alcohol Consumption with Psychosocial Outcomes among Colorectal Cancer Survivors 1-15 Years after Diagnosis. *Nutr Cancer*. 2022 Feb 25:1-9. doi: 10.1080/01635581.2022.2044063. Online ahead of print. Impactfactor: 2,816

Rijken A, van Erning FN, Rovers KP, Lemmens VE, de Hingh IH. On the origin of peritoneal metastases. *Eur J Cancer*. 2022 Dec 19;181:1-2. doi: 10.1016/j.ejca.2022.12.008. Online ahead of print. Impactfactor: 10,002

Scheepers ER, **Vink GR**, Schiphorst AH, Emmelot-Vonk MH, van Huis-Tanja LH, Hamaker ME. The impact of surgery and adjuvant chemotherapy on health-related quality of life in patients with colon cancer: Changes at group level versus individual level. *Eur J Cancer Care (Engl)*. 2022 Sep 2:e13691. doi: 10.1111/ecc.13691. Online ahead of print. Impactfactor: 2,328

Schraa SJ, van Rooijen KL, Koopman M, **Vink GR**, Fijneman RJ. Cell-Free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review. *Cancers (Basel)*. 2022 Apr 29;14(9):2218. doi: 10.3390/cancers14092218. Impactfactor: 6,575

Schuurman MS, Elferink MA, Verhoef C, **de Hingh IH, Lemmens VE**. Peritoneal metastases in elderly patients with colorectal cancer. *Eur J Surg Oncol*. 2022 May 18:S0748-7983(22)00438-3. doi: 10.1016/j.ejso.2022.05.013. Online ahead of print. Impactfactor: 4,037

Smit D, Mols F, Bonnhof CS, Bours ML, Vreugdenhil G, **Beijer S**. Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors? *Support Care Cancer*. 2022 Apr 13. doi: 10.1007/s00520-022-07036-z. Online ahead of print. Impactfactor: 3,359

Swartjes H, van Lankveld DW, **van Erning FN**, Verheul HM, de Wilt JH, Koëter T, **Vissers PA**. ASO Visual Abstract: Locoregionally Recurrent Colon Cancer: How Far Have We Come? a [population-based, retrospective cohort study. *Ann Surg Oncol*. 2022 Dec 19. doi: 10.1245/s10434-022-12782-9. Online ahead of print. Impactfactor: 4,339

Swartjes H, Brouwer NP, de Nes LC, **van Erning FN, Verhoeven RH, Vissers PA**, de Wilt JH. Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989. *Eur J Cancer*. 2022 Mar 12;166:134-144. doi: 10.1016/j.ejca.2022.01.029. Online ahead of print. Impactfactor: 10,002

Swartjes H, van Lankveld DW, **van Erning FN**, Verheul HM, de Wilt JH, Koëter T, **Vissers PA**. Locoregionally Recurrent Colon Cancer: How Far Have We Come? A Population-Based, Retrospective Cohort Study. *Ann Surg Oncol*. 2022 Oct 19. doi: 10.1245/s10434-022-12689-5. Online ahead of print. Impactfactor: 4,339

ten Hoorn S, **Mol L**, Sommeijer DW, Nijman L, van den Bosch T, de Back TR, Ylstra B, van Dijk E, van Noesel CJ, Reinten RJ, Nagtegaal ID, Koopman M, Punt CJ, Vermeulen L. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2022 Dec 5:S1533-0028(22)00132-3. doi: 10.1016/j.clcc.2022.11.006. Online ahead of print. Impactfactor: 4,035

ten Hoorn S, Waasdorp C, van Oijen MG, Damhofer H, Trinh A, Zhao L, Smits LJH, Bootsma S, van Pelt GW, Mesker WE, **Mol L**, Goey KK, Koopman M, Medema JP, Tuynman JB, Zlobec I, Punt CJ, Vermeulen L, Bijlsma MF. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. *BMC Cancer*. 2022 Apr 12;22(1):394. doi: 10.1186/s12885-022-09436-0. Impactfactor: 4,638

van der Heijden JA, Qaderi SM, **Verhoeven RH**, Custers JA, Klarenbeek BR, Maaskant-Braat AJ, de Wilt JH; PLCRC group. Author response to: Transanal total mesorectal excision and low anterior resection syndrome. *Br J Surg*. 2022 Feb 4;znac013. doi: 10.1093/bjs/znac013. Online ahead of print. Impactfactor: 11,782

van der Kruijssen DE, van der Kuil AJ, **Vink GR**, Punt CJ, de Wilt JH, Elias SG, Koopman M. Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a population-based study and meta-analysis. *Int J Cancer*. 2022 Nov 8. doi: 10.1002/ijc.34347. Online ahead of print. Impactfactor: 7,316

van der Meer R, Bakkens C, **van Erning FN**, Simkens LH, de Hingh IH, Roumen RM. A propensity score-matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases. *Int J Cancer*. 2022 Oct 17. doi: 10.1002/ijc.34325. Online ahead of print. Impactfactor: 7,316

van der Meer R, Jeuken JW, Bosch SL, **van Erning FN**, Simkens LH, de Hingh IH, Roumen RM. Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study. *J Cancer Res Clin Oncol*. 2022 Dec 21. doi: 10.1007/s00432-022-04502-3. Online ahead of print. Impactfactor: 4,322

van der Meer R, de Hingh IH, Coppus SF, **van Erning FN**, Roumen RM. Primary ovarian cancer after colorectal cancer: a Dutch nationwide population-based study. *Int J Colorectal Dis*. 2022 Jun 13. doi: 10.1007/s00384-022-04184-w. Online ahead of print. Impactfactor: 2,796

van Rooijen KL, Derksen JW, Verkooijen HM, **Vink GR**, Koopman M. Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer. *Int J Cancer*. 2022 Jun 3. doi: 10.1002/ijc.34149. Online ahead of print. Impactfactor: 7,316

van Zwam PH, Vink-Börger EM, Bronkhorst CM, de Bruine AP, van der Wurff AA, Rutten HJ, **Lemmens VE**, Nagtegaal ID, Hugen N. Prognosis of mucinous colon cancer is determined by histological biomarkers rather than microsatellite instability. *Histopathology*. 2022 Oct 10. doi: 10.1111/his.14818. Online ahead of print. Impactfactor: 7,778

Vissers PA, **Vink GR**, Koelink MR, Koopman M, **Arts LP**, **Oerlemans S**, May AM, **van de Poll-Franse LV**, **van Erning FN**. Evaluation of an individual feedback report on patient-reported outcomes in the Prospective Dutch ColoRectal Cancer cohort. *Support Care Cancer*. 2022 May 23. doi: 10.1007/s00520-022-07165-5. Online ahead of print. Impactfactor: 3,359

Zwanenburg ES, Wisselink DD, Klaver CE, Brandt AR, Bremers AJ, Burger JW, van Grevenstein WM, Hemmer PH, de Hingh IH, Kok NF, Wiezer MJ, Tuynman JB, Tanis PJ; COLOPEC trial collaborators (**Mol L**). Adhesion formation after surgery for locally advanced colonic cancer in the COLOPEC trial. *Br J Surg*. 2022 Mar 15;109(4):315-318. doi: 10.1093/bjs/znab467. Impactfactor: 11,782

4.2 Overige publicaties

Cardoso R, Guo F, Heisser T, De Schutter H, van Damme N, Nilbert MC, Christensen J, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszekiewicz M, Delafosse P, Poncet F, Walsh PM, Senore C, Rosso S, **Lemmens VE**, **Elferink MA**, Tomšič S, Žagar T, Marques AL, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Sánchez-Gil A, Chirlaque MD, Hoffmeister M, Brenner H. Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: a

population-based study in 9 countries. Lancet Reg Health Eur. 2022 Jul 6;21:100458. doi: 10.1016/j.lanepe.2022.100458. eCollection 2022 Oct.

4.3 Proefschriften en promoties

Lurvink RJ. Unresectable colorectal peritoneal metastases: exploring the role of PIPAC. Maastricht: Maastricht University; 7 april 2022. Promotor: **IH de Hingh**. Copromotores: JW Burger, **FN van Erning**.

Keikes L. Unresectable colorectal peritoneal metastases: exploring the role of PIPAC. Maastricht: Maastricht University; 7 april 2022. Promotores: CJ Punt, M Koopman. Copromotores: MH van Oijen, **VE Lemmens**.

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

Algera MD, van Driel WJ, Slangen BF, Kruitwagen RF, Wouters MW; participants of the Dutch Gynecological Oncology Collaborator group ([van der Aa MA](#)). Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'. *Gynecol Oncol*. 2022 Feb 22;S0090-8258(22)00123-8. doi: 10.1016/j.ygyno.2022.02.013. Online ahead of print. Impactfactor: 5,304

Bokkers K, Frederix GWJ, Velthuis ME, [van der Aa MA](#), Gerestein CG, van Dorst EB, Lange JG, Louwers JA, Koole W, Zweemer RP, Ausems MG. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective. *Gynecol Oncol*. 2022 Aug 25;S0090-8258(22)00550-9. doi: 10.1016/j.ygyno.2022.08.011. Online ahead of print. Impactfactor: 5,304

Broekman KE, [van der Aa MA](#), Nijman HW, Jalving M, Reyners AK. End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis. *Gynecol Oncol*. 2022 May 23;S0090-8258(22)00258-X. doi: 10.1016/j.ygyno.2022.04.017. Online ahead of print. Impactfactor: 5,304

Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, [van der Aa MA](#), Bray F, Soerjomataram I. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. *Int J Cancer*. 2022 Mar 23. doi: 10.1002/ijc.34002. Online ahead of print. Impactfactor: 7,316

Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, [Aben KK](#), Adank MA, Agata S, Andrusis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Borge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KB, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCs Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TV, Harris HR, Hartman M, Heitz F, Hildebrandt MA, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB; OCAC Consortium; CIMBA Consortium, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-

Trench G, Gayther SA, Antoniou AC, Pharoah PDP. [Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk](#). *Eur J Hum Genet*. 2022 Mar 22. doi: 10.1038/s41431-022-01085-y. Online ahead of print.
Impactfactor: 5,351

Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, **Aben KK**, Adank MA, Agata S, Andrusis IL, Anton-Culver H, Antonenkova NN, Aravantis G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Borge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Casingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KB, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitiv EN; KConFab Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB; OCAC Consortium; CIMBA Consortium, Thomassen M, Thompson PJ, Thomsen LC, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PD. [Polygenic risk modeling for prediction of epithelial ovarian cancer risk](#). *Eur J Hum Genet*. 2022 Jan 14. doi: 10.1038/s41431-021-00987-7. Online ahead of print.
Impactfactor: 5,351

de Vries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, **Aben KK**, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group, Håkansson N, Hildebrandt MA, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeny LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubiński J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PD, Easton DF, Gayther SA, Jones MR. [Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci](#). *J Natl Cancer Inst*. 2022 Oct 10:djac160. doi: 10.1093/jnci/djac160. Online ahead of print.
Impactfactor: 11,816

Drost LE, Stegeman M, Gerritse MB, Franx A, Vos MC; SHADE-POP study group, Lamers RED, [Ezendam NP](#), Dam A, Schrickx J, van Wijk HF. A web-based decision aid for shared decision making in pelvic organ prolapse: the SHADE-POP trial. *Int Urogynecol J*. 2022 Nov 15. doi: 10.1007/s00192-022-05405-0. Online ahead of print.
Impactfactor: 1,932

Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, Garcia MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCs Group, Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommos FKF, Kruitwagen RFP, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Toloczko A, Traficante N, Van de Vijver KK, [van der Aa MA](#), Van Gorp T, Van Nieuwenhuysen E, [van Wagensveld L](#), Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommos S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study. *Cancer*. 2022 Dec 26. doi: 10.1002/cncr.34582. Online ahead of print.
Impactfactor: 6,921

[Olthof EP](#), Mom CH, Snijders ML, [Wenzel HH](#), van der Velden J, [van der Aa MA](#). The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer. *Acta Obstet Gynecol Scand*. 2022 Feb 26. doi: 10.1111/aogs.14316. Online ahead of print.
Impactfactor: 4,544

[Olthof EP](#), [Wenzel H](#), van der Velden J, Spijkerboer AM, Bekkers R, Beltman JJ, Nijman HW, Slangen B, Smolders R, van Trommel N, Zusterzeel PL, Zweemer R, Stalpers LA, [van der Aa MA](#), Mom C. Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking. *Int J Gynecol Cancer*. 2022 Apr 28;ijgc-2022-003357. doi: 10.1136/ijgc-2022-003357. Online ahead of print.
Impactfactor: 4,661

ten Eikelder ML, Hinten F, Smits A, [van der Aa MA](#), Bekkers RLM, IntHout J, Wenzel HH, Zusterzeel PL. Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study. *Cancers (Basel)*. 2022 Jun 27;14(13):3140. doi: 10.3390/cancers14133140.
Impactfactor: 6,575

van der Horst RL, [van der Hel O](#), Lutgens L, [van der Aa MA](#), Slangen B, Kruitwagen R, Lalisang RI. The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review. *Crit Rev Oncol Hematol*. 2022 May 6:103701. doi: 10.1016/j.critrevonc.2022.103701. Online ahead of print.
Impactfactor: 6,625

van Nyen T, Planque M, [van Wagensveld L](#), Duarte JA, Zaal EA, Talebi A, Rossi M, Körner PR, Rizzotto L, Moens S, de Wispelaere W, Baiden-Amisshah RE, Sonke GS, Horlings HM, Eelen G, Berardi E, Swinnen JV, Berkers CR, Carmeliet P, Lambrechts D, Davidson B, Agami R, Fendt SM, Annibaldi D, Amant F. Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. *Nat Commun*. 2022 Aug 5;13(1):4578. doi: 10.1038/s41467-022-32272-6.
Impactfactor: 17,694

van Stein RM, Sikorska K, [van der Aa MA](#), Sonke GS, van Driel WJ; Dutch OVHIPEC-1 trial group. Evaluation of external validity of the OVHIPEC-1 trial in a real-world population. *Int J Gynaecol Obstet*. 2022 Dec 10. doi: 10.1002/ijgo.14618. Online ahead of print.
Impactfactor: 4,447

van Wagenveld L, van Baal JO, Timmermans M, Gaillard D, Borghuis L, Coffelt SB, Rosenberg EH, Lok CA, Nijman HW, Kooreman LF, Sanders J, de Bruijn M, Wessels LF, van der Wiel R, Rausch C, Broeks A, Kruitwagen RF, **van der Aa MA**, Sonke GS, Schouten PC, van de Vijver KK, Horlings HM. **Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer**. *Cancers (Basel)*. 2022 Dec 2;14(23):5965. doi: 10.3390/cancers14235965.

Impactfactor: 6,575

You B, **van Wagenveld L**, Tod M, Sonke GS, Horlings HM, Kruitwagen RF, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, **van der Aa MA**, Colomban O. **Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era**. *Br J Cancer*. 2022 Mar 31. doi: 10.1038/s41416-022-01732-7. Online ahead of print. Impactfactor: 9,802

5.2 Proefschriften en promoties

Wenzel HH. **Improving quality of cervical cancer care with (inter)national cancer registry data**. Groningen: Rijksuniversiteit Groningen; 3 juni 2022. Promotores: HW Nijmen, **VE Lemmens**, RL Bekkers. Copromotor: **MA van der Aa**.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Al-Sarayfi D, Meeuwes FO, **Durmaz M**, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PG, Böhmer LH, van der Poel MW, Te Boome L, van Meerten T, Chamuleau ME, Zijlstra JM, **Brink M**, Nijland M. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma. *Blood Cancer J*. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Impactfactor: 9,812

Bennink MC, Stege CA, Lissenberg-Witte BI, **Oerlemans S**, Seefat MR, Sonneveld P, Zweegman S. Impact of comorbidities on health-related quality of life in nontransplant eligible patients with newly diagnosed multiple myeloma. *Hemasphere*. 2022 Jun 21;6(7):e744. doi: 10.1097/HS9.0000000000000744. eCollection 2022 Jul. Impactfactor: 8,3

Boot MV, Schaapveld M, van den Broek EC, Hijmering NJ, Group P, van der Oord K, van Leeuwen FE, **Dinmohamed AG**, Koens L, de Jong D. Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nation-wide cohort: implications for clinical and epidemiological studies authors. *Haematologica*. 2022 Oct 20. doi: 10.3324/haematol.2022.280840. Online ahead of print. Impactfactor: 11,049

Brink M, Meeuwes FO, van der Poel MW, Kersten MJ, Wondergem M, Mutsaers PG, Bohmer LH, Woei-A-Jin FJ, Visser O, Oostvogels R, Jansen PM, Plattel WJ, Huls G, Vermaat JS, Nijland M. Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study. *Blood*. 2022 May 11: blood.2021015114. doi: 10.1182/blood.2021015114. Online ahead of print. Impactfactor: 25,669

Brink M, Minnema MC, **Visser O**, Levin MD, Posthuma EF, Broijl A, Sonneveld P, van der Klift M, Roeloffzen WW, Westerman M, van Rooijen CR, Geerts PA, Zweegman S, van de Donk NW, **Dinmohamed AG**. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. *Blood Cancer J*. 2022 Mar 15;12(3):41. doi: 10.1038/s41408-022-00640-6. Impactfactor: 9,812

Dinnessen MW, **Maas CC**, Tonino SH, **Visser O**, Posthuma EF, Blijlevens NM, Kersten MJ, Lugtenburg PJ, **Dinmohamed AG**. Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era. *Leukemia*. 2022 Mar 4. doi: 10.1038/s41375-022-01535-y. Online ahead of print. Impactfactor: 12,897

Durmaz M, **Visser O**, Posthuma EF, Brouwer RE, Issa DE, de Jong D, Lam KH, Blijlevens NM, Zijlstra JM, Chamuleau ME, Lugtenburg PJ, Kersten MJ, **Dinmohamed AG**. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018. *Blood Cancer J*. 2022 Mar 9;12(3):38. doi: 10.1038/s41408-022-00637-1. Impactfactor: 9,812

Ector GI, Geelen IG, **Dinmohamed AG**, Hoogendoorn M, Westerweel PE, Hermens RP, Blijlevens NM. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands. *Leuk Lymphoma*. 2022 Nov 11:1-9. doi: 10.1080/10428194.2022.2142055. Online ahead of print. Impactfactor: 2,996

Ekels A, van de Poll-Franse LV, Posthuma EF, Kieffer J, Issa DE, Koster A, Nijziel MR, Pruijt JH, Stevens WB, Tick LW, **Oerlemans S**. Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: a longitudinal PROFILES registry study. *Br J Haematol*. 2022 Apr 2. doi: 10.1111/bjh.18139. Online ahead of print. Impactfactor: 8,615

Kaplan ZL, van Leeuwen N, Posthuma EF, **Visser O**, Huls G, van de Loosdrecht AA, **Dinmohamed AG**. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something. *Leukemia*. 2022 Jan 17. doi: 10.1038/s41375-021-01503-y. Online ahead of print. Impactfactor: 12,897

Kockerols CC, Geelen I, Levin MD, Janssen JJ, **Dinmohamed AG**, Hoogendoorn M, Cornelissen JJ, Westerweel PE. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era. *Haematologica*. 2022 Mar 31. doi: 10.3324/haematol.2021.280501. Online ahead of print. Impactfactor: 11,049

Lindman A, **Duijts SF**, Olesen G, Handberg C. Patients' reflections on undergoing non-myeloablative allogeneic haematopoietic stem cell transplantation and participating in a multimodal interdisciplinary rehabilitation programme: a qualitative study. *Eur J Oncol Nurs*. 2022 Jan 2;56:102091. doi: 10.1016/j.ejon.2021.102091. Online ahead of print. Impactfactor: 2,588

Meeuwes FO, **Brink M**, van der Poel MW, Kersten MJ, Wondergem M, Mutsaers PG, Böhmer L, Woei-A-Jin S, Visser O, Oostvogels R, Jansen PM, Diepstra A, Snijders TJ, Plattel WJ, Huls GA, Vermaat JS, Nijland M. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. *Eur J Cancer*. 2022 Oct 5;176:100-109. doi: 10.1016/j.ejca.2022.09.008. Online ahead of print. Impactfactor: 10,002

Oerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K, Petranovic D, Borges FC, Bredart A, Shamieh O, Gziskevicius L, Lehmann J, Scholz CW, Caocci G, Molica S, Stamatopoulos K, Panteliadou AK, Papaioannou M, Alrjoob W, Baliakas P, Rosenquist R, Malak S, Miranda A, Cocks K, **van de Poll-Franse LV**; EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. *Br J Haematol*. 2022 Mar 7. doi: 10.1111/bjh.18072. Online ahead of print. Impactfactor: 8,615

Raa DG, **van der Straten L**, van Gelder M, Kersting S, Levin MD, Mous R, van der Straaten HM, Nijziel MR, van der Spek E, Posthuma EF, Visser HP, van der Klift M, de Heer K, Bellido M, Doorduyn JK, Bruns AH, Raijmakers RA, Kater AP; HOVON CLL study group. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. *Leuk Lymphoma*. 2022 Jun 23;1-14. doi: 10.1080/10428194.2022.2084731. Online ahead of print. Impactfactor: 2,996

Reedijk AM, Beishuizen A, Coebergh JW, Hoeben BA, Kremer LC, Hebeda KM, Pieters R, Loeffen JL, **Karim-Kos HE**. Progress against non-Hodgkin's lymphoma in children and young adolescents in the Netherlands since 1990: stable incidence, improved survival and lower mortality. *Eur J Cancer*. 2022 Jan 21;163:140-151. doi: 10.1016/j.ejca.2021.12.010. Online ahead of print. Impactfactor: 10,002

Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard JL, Girardi F, Fowler C, Marcos-Gragera R, Bonaventure A, Saint-Jacques N, Minicozzi P, De P, Rodríguez-Barranco M, Larønningen S, Di Carlo V, Mägi M, Valkov M, Seppä K, Wyn Huws D, Coleman MP, Allemani C; CONCORD Working Group (**Siesling S, Visser O**). Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. *Lancet Child Adolesc Health*. 2022 Jun;6(6):409-431. doi: 10.1016/S2352-4642(22)00095-5. Impactfactor: 37,746

van der Linde M, van Leeuwen N, Eijkenaar F, Rijnveld AW, Pieters R, **Karim-Kos HE**. Effect of Treatment in a Specialized Pediatric Hemato-Oncology Setting on 5-Year Survival in Acute Lymphoblastic Leukemia: A Quasi-Experimental Study. *Cancers (Basel)*. 2022 May 16;14(10):2451. doi: 10.3390/cancers14102451. Impactfactor: 6,575

van der Straten L, Maas CC, Levin MD, **Visser O**, Posthuma EF, Doorduijn JK, Langerak AW, Kater AP, **Dinmohamed AG**. Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018. *Blood Cancer J*. 2022 Apr 20;12(4):72. doi: 10.1038/s41408-022-00669-7. Impactfactor: 9,812

van Zeventer IA, de Graaf AO, Koorenhof-Scheele TN, van der Reijden BA, van der Klauw M, **Dinmohamed AG**, Diepstra A, Schuringa JJ, Malcovati L, Huls G, Jansen JH. Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. *Blood Adv*. 2022 May 13;bloodadvances.2021006755. doi: 10.1182/bloodadvances.2021006755. Online ahead of print. Impactfactor: 7,642

Weehuizen JM, van Roeden SE, **Hogewoning SJ**, van der Hoek W, Bonten MJ, Hoepelman AI, Bleeker-Rovers CP, Wever PC, Oosterheert JJ. No increased risk of mature B-cell non-Hodgkin lymphoma after Q fever detected: results from a 16-year ecological analysis of the Dutch population incorporating the 2007-2010 Q fever outbreak. *Int J Epidemiol*. 2022 Mar 30;dyac053. doi: 10.1093/ije/dyac053. Impactfactor: 9,685

Wester R, **Dinmohamed AG**, van der Holt B, Zweegman S, Minnema M, Croockewit S, Levin MD, Libourel E, de Waal E, Sonneveld P, Cornelissen J, Blijlevens N, Broijl A. Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry. *Hemasphere*. 2022 Jan 27;6(2):e683. doi: 10.1097/HS9.0000000000000683. eCollection 2022 Feb. Impactfactor: 8,3

6.2 Overige publicaties

van der Straten L, Levin MD, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. Conditional relative survival among patients with chronic lymphocytic leukaemia: a population-based study in the Netherlands. *EJHaem*. 2021 Dec 20;3(1):180-183. doi: 10.1002/jha2.368. eCollection 2022 Feb.

van Lieshout R, **Lize N**, Tick LW, van Deursen J, Driessen E, Janssen T, Custers S, Kranenburg S, van der Lee D, Koene HR, Beckers EA, Schouten HC, **Beijer S**. Nutrition-related problems, nutritional support practices and barriers to adherence to nutritional guidelines during intensive treatment for acute myeloid leukemia: Patients' and hematology nurses' perspectives and experiences. *Clin Nutr ESPEN*. 2022 Apr;48:446-455. doi: 10.1016/j.clnesp.2021.12.029. Epub 2022 Jan 1.

6.3 Proefschriften en promoties

Dinnessen MA. Deciphering the epidemiology of follicular lymphoma: population-based studies in the Netherlands. Amsterdam: Universiteit van Amsterdam; 20 oktober 2022. Promotor: MJ Kersten. Copromotores: **AG Dinmohamed**, PJ Lugtenburg.

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Brands MT, Swinkels IJ, Aarts AM, Verbeek AL, **Merkx MA**, Marres HA, Kaanders JH, Melchers WJ, van Engen-van Grunsven I, Takes RP, Geurts SM. Value of routine follow-up in oropharyngeal squamous cell cancer patients treated with curative intent. *Head Neck*. 2022 Dec 24. doi: 10.1002/hed.27269. Online ahead of print.

Impactfactor: 3,821

Lebbink CA, van den Broek MF, **Kwast AB**, Derikx JP, Dierselhuis MP, Kruijff S, Links TP, van Trotsenburg AS, Valk GD, Vriens MR, Verrijn Stuart AA, van Santen HM, **Karim-Kos HE**. Correction: Lebbink et al. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span. *Cancers* 2021, 13, 5104. *Cancers* (Basel). 2022 Jun 14;14(12):2929. doi: 10.3390/cancers14122929.

Impactfactor: 6,575

Leus AJ, **van Dijk BA**, Postmus D, Plaat BE, Halmos GB, Diercks GF, Rácz E, van Kester MS. "Prediction of poor outcome for cutaneous squamous cell carcinoma of the head and neck comparing classification systems: a competing risk analysis". *J Invest Dermatol*. 2022 Mar 15:S0022-202X(22)00199-3. doi: 10.1016/j.jid.2022.02.015.

Impactfactor: 7,59

Ruiter LN, **van Dijk BA**, Bruggink AH, Doornaert PA, Philippens ME, de Bree R, van Gils CH, Willems SM. Association of histological features with laryngeal squamous cell carcinoma recurrences: a population-based study of 1502 patients in the Netherlands. *BMC Cancer*. 2022 Apr 22;22(1):444. doi: 10.1186/s12885-022-09533-0.

Impactfactor: 4,638

Schoonbeek RC, Festen S, Rashid R, **van Dijk BA**, Halmos GB, van der Velden LA. Impact of Delay on Hospitalization in Older Patients With Head and Neck Cancer: a Multicenter Study. *Otolaryngol Head Neck Surg*. 2022 Oct;167(4):678-687. doi: 10.1177/01945998211072828. Epub 2022 Jan 19.

Impactfactor: 5,591

Schoonbeek RC, de Jel DV, **van Dijk BA**, Willems SM, Bloemena E, Hoebbers FJ, van Meerten E, Verbist BM, Smeele LE, Halmos GB, **Merkx MA**, **Siesling S**, de Bree R, Takes RP; Dutch Head and Neck Society and the COVID and Cancer-NL consortium. Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence". *Radiother Oncol*. 2022 Jan 29:S0167-8140(22)00033-0. doi: 10.1016/j.radonc.2022.01.029. Online ahead of print.

Impactfactor: 6,901

Schoonbeek RC, Festen S, van der Laan BF, Plaat BE, Langendijk JA, **van Dijk BA**, Halmos GB. The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients. *Radiother Oncol*. 2022 Jun 6:S0167-8140(22)04146-9. doi: 10.1016/j.radonc.2022.06.001. Online ahead of print.

Impactfactor: 6,901

Schoonbeek RC, de Vries J, Bras L, Sidorenkov G, Plaat BE, Witjes MJ, van der Laan BF, van den Hoek JG, **van Dijk BA**, Langendijk JA, Halmos GB. The effect of treatment delay on quality of life and overall survival in head and neck cancer patients. *Eur J Cancer Care (Engl)*. 2022 Apr 19:e13589. doi: 10.1111/ecc.13589. Online ahead of print.

Impactfactor: 2,328

Schreuder WH, Lipplaa A, Cleven AH, van den Berg H, Bisschop PH, de Jongh RT, Witjes MJ, Kessler PA, **Merkx MA**, Edelenbos E, Klop C, Schreurs R, Westermann AM, Tromp JM, Levenga H, Gelderblom H, de Lange J. RANKL inhibition for giant cell lesions of the jaw: a retrospective cohort analysis. *Eur J Cancer*. 2022 Sep 26;175:263-273. doi: 10.1016/j.ejca.2022.08.011. Online ahead of print.

Impactfactor: 10,002

van Dijk D, Groen AH, [van Dijk BA](#), van Veen TL, Sluiter WJ, Links TP, Plukker JT. Outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines. Clin Endocrinol (Oxf). 2022 Jul 3. doi: 10.1111/cen.14795. Online ahead of print. Impactfactor: 3,523

van Leer B, Leus AJ, [van Dijk BA](#), van Kester MS, Halmos GB, Diercks GF, van der Vegt B, Vister J, Rácz E, Plaat BE. The Effect of Tumor Characteristics and Location on the Extent of Lymph Node Metastases of Head and Neck Cutaneous Squamous Cell Carcinoma. Front Oncol. 2022 May 30;12:874295. doi: 10.3389/fonc.2022.874295. eCollection 2022. Impactfactor: 5,738

7.2 Overige publicaties

van Tilburg L, [Brands MT](#), Koch AD. To screen or not to screen: Reply to "Long-term results of an endoscopic screening program for superficial esophageal cancer in patients with head and neck squamous cell carcinoma". Endosc Int Open. 2022 Oct 17;10(10):E1328-E1329. doi: 10.1055/a-1916-8878. eCollection 2022 Oct.

8 Huidkanker

8.1 Publicaties met impactfactor

Eggermont C, Wakkee M, Bruggink A, Voorham Q, **Schreuder K, Louwman M**, Mooyaart A, Hollestein L. Development and validation of an algorithm to identify patients with advanced cutaneous squamous cell carcinoma from pathology reports. *J Invest Dermatol*. 2022 Aug 1:S0022-202X(22)01686-4. doi: 10.1016/j.jid.2022.07.008. Online ahead of print. Impactfactor: 7,59

Fraterman I, Glaser SL, Wilgenhof S, Medlock SK, Mallo HA, Cornet R, **van de Poll-Franse LV**, Boekhout AH. Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study. *Support Care Cancer*. 2022 May 19:1-12. doi: 10.1007/s00520-022-07133-z. Online ahead of print. Impactfactor: 3,359

Lemmens VE, Louwman MW. Basal cell carcinoma, an often unjustly overlooked healthcare challenge. *Br J Dermatol*. 2022 Apr 28. doi: 10.1111/bjd.21587. Online ahead of print. Impactfactor: 11,113

Mulder EE, Johansson I, Grünhagen DJ, Tempel D, Rentroia-Pacheco B, Dwarkasing JT, Verver D, Mooyaart AL, van der Veldt AA, Wakkee M, Nijsten TE, Verhoef C, Mattsson J, Ny L, **Hollestein LM**, Olofsson Bagge R. Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk of disease relapse. *Cancers (Basel)*. 2022 Jun 9;14(12):2854. doi: 10.3390/cancers14122854. Impactfactor: 6,575

Reijers IL, Menzies AM, van Akkooi AC, Versluis JM, van den Heuvel NM, Saw RP, Pennington TE, Kapiteijn E, van der Veldt AA, Suijkerbuijk KP, Hospers GA, Rozeman EA, Klop WM, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Józwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JB, Rawson RV, van de Wiel BA, **van de Poll-Franse LV**, Scolyer RA, Boekhout AH, Long GV, Blank CU. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. *Nat Med*. 2022 Jun 5. doi: 10.1038/s41591-022-01851-x. Online ahead of print. Impactfactor: 87,244

Sangers TE, Wakkee M, Kramer-Noels EC, Nijsten T, **Louwman MW**, Jaspars EH, **Hollestein L**. Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: a nationwide pathology registry analysis. *Br J Dermatol*. 2022 Feb 10. doi: 10.1111/bjd.21050. Online ahead of print. Impactfactor: 11,113

Singh K, **Schreuder K, Stuijver D**, Vrijman C, **Louwman MW**. Seasonal variation in diagnosis of cutaneous invasive melanoma and cutaneous squamous cell carcinoma: A nationwide study in the Netherlands. *Cancer Epidemiol*. 2022 Nov 7;81:102289. doi: 10.1016/j.canep.2022.102289. Online ahead of print. Impactfactor: 2,89

Slotman E, Schreuder K, Nijsten TEC, Wakkee M, **Hollestein L**, Mooyaart A, **Siesling S, Louwman MW**. The impact of the COVID-19 pandemic on keratinocyte carcinoma in the Netherlands: trends in diagnoses and magnitude of diagnostic delays. *J Eur Acad Dermatol Venereol*. 2022 Jan 28. doi: 10.1111/jdv.17976. Online ahead of print. Impactfactor: 9,228

Tokez S, Venables ZC, **Hollestein LM**, Qi H, Bramer EM, Rentroia-Pacheco B, van den Bos RR, Rous B, Leigh IM, Nijsten T, Mooyaart AL, Wakkee M. Risk factors for metastatic cutaneous squamous cell carcinoma: refinement and replication based on two nationwide nested case-control studies. *J Am Acad Dermatol*. 2022 Mar 5:S0190-9622(22)00371-1. doi: 10.1016/j.jaad.2022.02.056. Online ahead of print. Impactfactor: 15,487

van Egmond S, van Vliet ED, Wakkee M, **Hollestein LM**, Pouwels XG, Koffijberg H, Misirli Y, Bakkum RS, Bastiaens MT, Kukutsch NA, Oosting AJ, Plasmeijer EI, van Rengen A, de Roos KP, Nijsten TE, de Vries E, de Bekker-Grob EW. Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care. PLoS One. 2022 Jan 24;17(1):e0260978. doi: 10.1371/journal.pone.0260978. eCollection 2022.
Impactfactor: 3,752

9 Longkanker

9.1 Publicaties met impactfactor

de Rooij BH, van den Hurk C, Smaardijk V, Fernandez-Ortega P, Navarro-Martin A, Barberio L, Guckenberger M, Schmid S, Walraven I, Vallow S, Kotsi C, Preusser M, Mosor E, Klok JM, Becker A, Milani A, Ninov L, **van de Poll-Franse LV**. Development of an updated, standardized, patient-centered outcome set for lung cancer. *Lung Cancer*. 2022 Sep 5;173:5-13. doi: 10.1016/j.lungcan.2022.08.021. Online ahead of print. Impactfactor: 6,081

de Ruiter JC, van Diessen JN, Smit EF, van der Noort V, **Damhuis RA**, Hartemink KJ; ESLUNG group. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer. *Eur J Cardiothorac Surg*. 2022 Mar 28;ezac118. doi: 10.1093/ejcts/ezac118. Online ahead of print. Impactfactor: 4,534

Dieleman E, van der Woude L, van Os R, van Bockel L, Coremans I, van Es C, de Jaeger K, Knol HP, Kolff W, Koppe F, Pomp J, Reymen B, Schinagl D, Spoelstra F, Tissing-Tan C, van der Voort van Zyp N, van der Wel A, Wijsman R, Dielwart M, Wiegman E, **Damhuis R**, Belderbos J. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation. *Clin Lung Cancer*. 2022 Nov 25:S1525-7304(22)00266-2. doi: 10.1016/j.clc.2022.11.008. Online ahead of print. Impactfactor: 4,84

Klarenbeek SE, **Aarts MJ**, van den Heuvel MM, Prokop M, Tummers M, Schuurbijs OC. Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study. *Thorax*. 2022 Apr 21;thoraxjnl-2021-218059. doi: 10.1136/thoraxjnl-2021-218059. Online ahead of print. Impactfactor: 9,203

Steeghs EM, Groen HJ, Schuurings E, **Aarts MJ, Damhuis RA**, Voorham QJ; PATH consortium, Ligtenberg ML, Grünberg K. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. *Lung Cancer*. 2022 May;167:87-97. doi: 10.1016/j.lungcan.2022.04.001. Impactfactor: 6,081

ten Berge DM, **Aarts MJ**, Groen HJ, Aerts JG, Kloover JS. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. *Eur J Cancer*. 2022 Mar 3;165:195-204. doi: 10.1016/j.ejca.2022.01.038. Online ahead of print. Impactfactor: 10,002

van Kooten JP, Belderbos RA, von der Thüsen JH, **Aarts MJ**, Verhoef C, Burgers JA, Baas P, Aalbers AG, Maat AP, Aerts JG, Cornelissen R, Madsen EV. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. *Thorax*. 2022 Feb 11;thoraxjnl-2021-217709. doi: 10.1136/thoraxjnl-2021-217709. Online ahead of print. Impactfactor: 9,203

10 Neuro-endocriene tumoren

10.1 Publicaties met impactfactor

Poleé IN, Hermans BCM, [van der Zwan JM](#), Bouwense SAW, Dercksen MW, Eskens FALM, Havekes B, Hofland J, Kerkhofs TMA, Klümpen HJ, Latten-Jansen LM, Speel EM, Verburg FA, Walenkamp AME, Geurts SME, de Vos-Geelen J. [Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study](#). Eur J Cancer. 2022 Jul 5;172:252-263. doi: 10.1016/j.ejca.2022.06.003. Online ahead of print.
Impactfactor: 10,002

11 Neuro-oncologie

11.1 Publicaties met impactfactor

Albers EA, de Ruiter MB, [van de Poll-Franse LV](#), Merckel LG, Compter A, Schagen SB. Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases. *J Neurooncol.* 2022 Dec;160(3):649-658. doi: 10.1007/s11060-022-04185-3. Epub 2022 Dec 1. Impactfactor: 4,506

Girardi F, Di Carlo V, Stiller C, Gatta G, Woods RR, [Visser O](#), Lacour B, Tucker TC, Coleman MP, Allemani C; CONCORD Working Group. Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). *Neuro Oncol.* 2022 Oct 10:noac232. doi: 10.1093/neuonc/noac232. Online ahead of print. Impactfactor: 13,029

Hoogendijk R, van der Lugt J, van Vuurden DG, [Visser O](#), [Karim-Kos HE](#). Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al. *Neuro Oncol.* 2022 May 21:noac039. doi: 10.1093/neuonc/noac039. Online ahead of print. Impactfactor: 13,029

Hoogendijk R, van der Lugt J, Hoving E, Kremer L, [Visser O](#), Wesseling P, van Vuurden D, [Karim-Kos H](#). The 5th edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries. *Neuro Oncol.* 2022 Jul 25:noac176. doi: 10.1093/neuonc/noac176. Online ahead of print. Impactfactor: 13,029

[Simões Padilla C](#), [Ho VY](#), [van der Strate IH](#), Leenders WP, de Vos FY, Veldhuijzen van Zanten SE, [Loef C](#). Prognostic factors among patients with brain metastases from cancer of unknown primary site. *J Neurooncol.* 2022 Aug 17. doi: 10.1007/s11060-022-04106-4. Online ahead of print. Impactfactor: 4,506

11.2 Overige publicaties

[Ho VK](#), Gijtenbeek AJ, Wagemakers M, Taal W, van Linde ME, Swaak-Kragten AT, Kurt E, van der Weide HL, Wesseling P, de Vos FY, Bromberg JE. Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors. *Neurooncol Adv.* 2022 Apr 22;4(1):vdac062. doi: 10.1093/oaajnl/vdac062. eCollection 2022 Jan-Dec.

12 Upper GI & HPB

12.1 Publicaties met impactfactor

Al-Kaabi A, Baranov NS, van der Post RS, Schoon EJ, Rosman C, van Laarhoven HW, Verheij M, **Verhoeven RH**, Siersema PD. Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study. *Acta Oncol.* 2022 Feb 3:1-8. doi: 10.1080/0284186X.2021.2024878. Online ahead of print. Impactfactor: 4,311

Belkouz A, van Roessel S, Strijker M, van Dam JL, Daamen L, **van der Geest LG**, Balduzzi A, Cacciaguerra AB, van Dieren S, Molenaar Q, Groot Koerkamp B, Verheij J, van Eycken E, Malleo G, Hilal MA, van Oijen MG, Borbath I, Verslype C, Punt CJ, Besselink MG, Klumpen HJ; Dutch Pancreatic Cancer Group (DPCG). Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. *Br J Cancer.* 2022 Jan 17. doi: 10.1038/s41416-021-01687-1. Impactfactor: 9,082

de Jong EJ, Mommers I, Fariña Sarasqueta A, **van der Geest LG**, Heij L, de Hingh IH, Homs MY, Tjan-Heijnen VC, Valkenburg-van Iersel LB, Wilmink JW, Geurts SM, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. *Acta Oncol.* 2022 Apr 5:1-6. doi: 10.1080/0284186X.2022.2053199. Online ahead of print. Impactfactor: 4,311

de Jong EJ, **van der Geest LG**, Besselink MG, Bouwense SA, Buijsen J, Dejong CH, Koerkamp BG, Heij LR, de Hingh IH, Hoge C, Kazemier G, van Laarhoven HW, de Meijer VE, Stommel MW, Tjan-Heijnen VC, Valkenburg-van Iersel LB, Wilmink JW, Geurts SM, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. *HPB (Oxford).* 2022 Jan 23:S1365-182X(22)00044-2. doi: 10.1016/j.hpb.2022.01.009. Online ahead of print. Impactfactor: 3,842

Dijksterhuis WP, Kroese TE, **Verhoeven RH**, van Rossum PS, Mook S, Haj Mohammad N, Hulshof MC, Gisbertz SS, Ruurda JP, **van Oijen MG**, van Hillegersberg R, van Laarhoven HW. A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. *Eur J Surg Oncol.* 2022 Mar 18:S0748-7983(22)00125-1. doi: 10.1016/j.ejso.2022.03.003. Online ahead of print. Impactfactor: 4,037

Fransen LF, **Verhoeven RH**, Janssen TH, van Det MJ, Gisbertz SS, van Hillegersberg R, Klarenbeek B, Kouwenhoven EA, Nieuwenhuijzen GA, Rosman C, Ruurda JP, van Berge Henegouwen MI, Luyer MD. The association between postoperative complications and long-term survival after esophagectomy: a multicenter cohort study. *Dis Esophagus.* 2022 Dec 6:doac086. doi: 10.1093/dote/doac086. Online ahead of print. Impactfactor: 2,822

Hopstaken JS, **Vissers PA**, Quispel R, de Vos-Geelen J, Brosens LA, de Hingh IH, **van der Geest LG**, Besselink MG, van Laarhoven KJ, Stommel MW; Dutch Pancreatic Cancer Group. Impact of multicentre diagnostic workup in patients with pancreatic cancer on repeated diagnostic investigations, time-to-diagnosis and time-to-treatment: a nationwide analysis. *Eur J Surg Oncol.* 2022 Jun 2:S0748-7983(22)00481-4. doi: 10.1016/j.ejso.2022.05.031. Online ahead of print. Impactfactor: 4,037

Huang L, Jansen L, **Verhoeven RH**, Ruurda JP, van Eycken L, de Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Lagarde SM, van de Velde CJ, Schrotz-King P, Brenner H. Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates. *Cancer Commun (Lond).* 2022 Jun 6. doi: 10.1002/cac2.12318. Online ahead of print. Impactfactor: 15,283

Jeene PM, Kuijper SC, van den Boorn HG, El Sharouni SY, Braam PM, Oppedijk V, **Verhoeven RH**, Hulshof MC, van Laarhoven HW. Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia. *Acta Oncol.* 2022 Jun 1:1-7. doi: 10.1080/0284186X.2022.2079385. Online ahead of print. Impactfactor: 4,311

Kroese TE, Takahashi Y, Lordick F, van Rossum PS, Ruurda JP, Lagarde SM, van Hillegersberg R, **Verhoeven RH**, van Laarhoven HW. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. *Eur J Cancer.* 2022 Nov 15;179:65-75. doi: 10.1016/j.ejca.2022.11.011. Online ahead of print. Impactfactor: 10,002

Kroese TE, Jorritsma NK, van Laarhoven HW, **Verhoeven RH**, Mook S, Haj Mohammad N, Ruurda JP, van Rossum PS, van Hillegersberg R. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study. *Clin Transl Radiat Oncol.* 2022 Aug 24;37:109-115. doi: 10.1016/j.ctro.2022.08.012. eCollection 2022 Nov. Impactfactor: 4,739

Kuijper SC, **Pape M**, Haj Mohammad N, van Voorthuizen T, **Verhoeven RH**, van Laarhoven HW. SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy. *Int J Cancer.* 2022 Nov 30. doi: 10.1002/ijc.34385. Online ahead of print. Impactfactor: 7,316

Luijten JC, **Vissers PA**, **Brom L**, de Bièvre M, Buijsen J, Rozema T, Mohammad NH, van Duijvendijk P, Kouwenhoven EA, Eshuis WJ, Rosman C, Siersema PD, van Laarhoven HW, **Verhoeven RH**, Nieuwenhuijzen GA, Westerman MJ. Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study. *BMC Health Serv Res.* 2022 Apr 20;22(1):527. doi: 10.1186/s12913-022-07845-2. Impactfactor: 2,908

Luijten JC, Westerman MJ, Nieuwenhuijzen GA, Walraven JE, Sosef MN, Beerepoot LV, van Hillegersberg R, Muller K, Hoekstra R, Bergman JJ, Siersema PD, van Laarhoven HW, Rosman C, **Brom L**, **Vissers PA**, **Verhoeven RH**. Team dynamics and clinician's experience influence decision-making during Upper-GI multidisciplinary team meetings: a multiple case study. *Front Oncol.* 2022 Oct 18;12:1003506. doi: 10.3389/fonc.2022.1003506. eCollection 2022. Impactfactor: 5,738

Luijten JC, **Brom L**, **Vissers PA**, van de Wouw YA, Warmerdam FA, Heisterkamp J, Mook S, Oulad Hadj J, van Det MJ, Timmermans L, Hulshof MC, van Laarhoven HW, Rosman C, Siersema PD, Westerman MJ, **Verhoeven RH**, Nieuwenhuijzen GA. Treatment decision-making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study. *Cancer Med.* 2022 Feb 15. doi: 10.1002/cam4.4596. Online ahead of print. Impactfactor: 4,711

Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, **Verhoeven RH**, Vignat J, Laversanne M, Ferlay J, Soerjomataram I. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. *EClinicalMedicine.* 2022 Apr 21;47:101404. doi: 10.1016/j.eclinm.2022.101404. eCollection 2022 May. Impactfactor: 17,033

Neelis KJ, Kip DM, Speetjens FM, **van der Linden YM**. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis. *Radiat Oncol.* 2022 Apr 20;17(1):81. doi: 10.1186/s13014-022-02049-8. Impactfactor: 4,309

Pape M, **Vissers PA**, Beerepoot LV, van Berge Henegouwen MI, Lagarde SM, Mook S, Moehler M, van Laarhoven HW, **Verhoeven RH**. A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. *Ther Adv Med Oncol.* 2022 Feb 26;14:17588359221075495. doi: 10.1177/17588359221075495. eCollection 2022. Impactfactor: 5,485

Pape M, Vissers PA, Bertwistle D, McDonald L, Slingerland M, Haj Mohammad N, Beerepoot LV, Ruurda JP, Nieuwenhuijzen GA, Jeene PM, van Laarhoven HW, **Verhoeven RH**. A population-based study in synchronous *versus* metachronous metastatic esophagogastric adenocarcinoma. *Ther Adv Med Oncol*. 2022 Mar 24;14:17588359221085557. doi: 10.1177/17588359221085557. eCollection 2022. Impactfactor: 5,485

Pape M, Kuijper SC, **Vissers PA**, Beerepoot LV, Creemers GJ, van Laarhoven HW, **Verhoeven RH**. Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer. *J Natl Compr Canc Netw*. 2022 Dec;20(12):1321-1329.e4. doi: 10.6004 /jncn.2022.7066. Impactfactor: 12,693

Pape M, Vissers PA, Bertwistle D, McDonald L, Beerepoot LV, van Berge Henegouwen MI, Lagarde SM, Mook S, Mohammad NH, Jeene PM, van Laarhoven HW, **Verhoeven RH**. Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer. *Br J Surg*. 2022 Aug 23:znac290. doi: 10.1093/bjs/znac290. Online ahead of print. Impactfactor: 11,782

Pape M, Vissers PA, de Vos-Geelen J, Hulshof MC, Gisbertz SS, Jeene PM, van Laarhoven HW, **Verhoeven RH**. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: a population-based study. *Cancer Sci*. 2022 Jan 5. doi: 10.1111/cas.15262. Online ahead of print. Impactfactor: 6,518

Pijnappel EN, **Schuurman M**, Wagner AD, de Vos-Geelen J, **van der Geest LG**, de Groot JB, Koerkamp BG, de Hingh IH, Homs MY, Creemers GJ, Cirkel GA, van Santvoort HC, Busch OR, Besselink MG, van Eijck CH, Wilmink JW, van Laarhoven HW. Sex, gender and age differences in treatment allocation and survival of patients with metastatic pancreatic cancer: a nationwide study. *Front Oncol*. 2022 Mar 24;12:839779. doi: 10.3389/fonc.2022.839779. eCollection 2022. Impactfactor: 5,738

Pijnappel EN, **Dijksterhuis WP**, Sprangers MA, Augustinus S, de Vos-Geelen J, de Hingh IH, Molenaar IQ, Busch OR, Besselink MG, Wilmink JW, van Laarhoven HW; Dutch Pancreatic Cancer Group. The fear of cancer recurrence and progression in patients with pancreatic cancer. *Support Care Cancer*. 2022 Feb 15. doi: 10.1007/s00520-022-06887-w. Online ahead of print. Impactfactor: 3,359

Schipper RJ, **de Hingh IH**, Luyer MD. Teres ligamentum wrap covering the pancreaticojejunostomy following pancreatoduodenectomy is associated with a lower rate of postoperative pancreas fistula: a prospective cohort study. *HPB (Oxford)*. 2022 Oct 8:S1365-182X(22)01609-4. doi: 10.1016/j.hpb.2022.10.002. Online ahead of print. Impactfactor: 3,842

Stroes CI, Schokker S, Khurshed M, van der Woude SO, Mathôt RA, Slingerland M, de Vos-Geelen J, Zucchetti M, Matteo C, van Dijk E, Ylstra B, Thijssen V, Derks S, Godefa T, Dijksterhuis W, Breimer GE, van Delden OM, **Verhoeven RH**, Meijer SL, Bijlsma MF, van Laarhoven HW. A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). *Ther Adv Med Oncol*. 2022 Jun 28;14:17588359221109196. doi: 10.1177/17588359221109196. Impactfactor: 5,485

van Hove JC, Verhoeven RH, Nagengast WB, Oppedijk V, Lynch MG, van Rooijen JM, Veldhuis P, **Siesling S**, Kouwenhoven EA. Managed Clinical Network for esophageal cancer enables reduction of variation between hospitals trends in treatment strategies, lead time, and 2-year survival. *Eur J Surg Oncol*. 2022 Aug 2:S0748-7983(22)00583-2. doi: 10.1016/j.ejso.2022.07.022. Online ahead of print. Impactfactor: 4,037

Versteijne E, van Dam JL, Suker M, Janssen QP, **Groothuis K**, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FA, Festen S, de Groot JW, Groot Koerkamp B, de Hingh IH, Homs MY, van Hooft JE, Kerver ED, Luelmo SA, Neelis KJ, Nuyttens J, Paardekooper GM, Patijn GA, van der Sangen MJ, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CH; Dutch Pancreatic Cancer Group. **Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.** J Clin Oncol. 2022 Jan 27;JCO2102233. doi: 10.1200/JCO.21.02233. Online ahead of print. Impactfactor: 50,739

12.2 Overige publicaties

Adriaans DJ, **Beijer S**, Heesakkers FF, de Craen-Kat L, **Horevoorts N**, Dierick-van Daele A, Teijink JA, van Laarhoven HW, **van de Poll-Franse LV**, Nieuwenhuijzen GA. Effect of a pre-operative web-based dietary self-management intervention on patient satisfaction, body weight and quality of life of esophageal cancer patients: a prospective, observational study. Clinical Nutrition Open Science 2022 June, pp. 42-55.

12.3 Proefschriften en promoties

Luijten J. Insights in variation in oncological upper GI Practice. Rotterdam: Erasmus Universiteit; 22 december 2022. Promotores: **V Lemmens**, G Nieuwenhuijzen, **RH Verhoeven**, **PA Vissers**.

13 Urogenitale kanker

13.1 Publicaties met impactfactor

Boer H, Lubberts S, Bunschoek S, Nuver J, Lefrandt JD, Steursma G, Sluiter WJ, **Siesling S**, Berendsen AJ, Gietema JA. Shared-care survivorship program for testicular cancer patients: safe and feasible. *ESMO Open*. 2022 May 13;7(3):100488. doi: 10.1016/j.esmoop.2022.100488. Online ahead of print. Impactfactor: 6,883

Bokhorst LP, **Heesterman BL**. Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. *Eur Urol*. 2022 Jul 25:S0302-2838(22)02482-4. doi: 10.1016/j.eururo.2022.07.004. Online ahead of print. Impactfactor: 24,344

Creemers SG, van Santvoort B, van den Berkmortel FW, Kiemeny LA, van Oort IM, **Aben KK**, Hamberg P; ProZIB. Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice. *Prostate Cancer Prostatic Dis*. 2022 Jul 7. doi: 10.1038/s41391-022-00556-z. Online ahead of print. Impactfactor: 5,455

Evers J, Kerkmeijer LG, van den Bergh RC, van der Sangen MJ, Hulshof MC, Bloemers M, **Siesling S**, **Aarts MJ**, **Aben KK**, Struikmans H. Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: a 12-year nationwide overview from The Netherlands. *Radiother Oncol*. 2022 Oct 31:S0167-8140(22)04523-6. doi: 10.1016/j.radonc.2022.10.028. Online ahead of print. Impactfactor: 6,901

Galceran J, Parada D, Eden M, Tumino R, Warren AY, Martos C, Neamtiu L, **Visser O**, Daubisse-Marliac L. The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract. *Front Oncol*. 2022 Nov 23;12:1046239. doi: 10.3389/fonc.2022.1046239. eCollection 2022. Impactfactor: 5,738

Maurits JS, Sedelaar JP, **Aben KK**, Kiemeny LA, Vrieling A. Association of visceral and subcutaneous adiposity with tumor stage and Fuhrman grade in renal cell carcinoma. *Sci Rep*. 2022 Oct 6;12(1):16718. doi: 10.1038/s41598-022-20877-2. Impactfactor: 4,997

Maurits JS, Sedelaar JP, **Aben KK**, Kiemeny LA, Vrieling A. The association of body composition with postoperative complications and length of hospital stay after radical or partial nephrectomy in patients with renal cell cancer: a multicenter population-based cohort study. *Transl Androl Urol*. 2022 Dec;11(12):1667-1679. doi: 10.21037/tau-22-367. Impactfactor: 2,479

Richters A, Kiemeny LA, Mehra N, Westgeest HM, Birtle A, Bryan RT, **Aben KK**. Evidence or Prejudice? Critical Re-analysis of randomized controlled trials comparing overall survival after cisplatin versus carboplatin-cased regimens in advanced urothelial carcinoma. *Clin Genitourin Cancer*. 2021 Dec 27:S1558-7673(21)00251-2. doi: 10.1016/j.clgc.2021.12.017. Online ahead of print. Impactfactor: 3,121

Richters A, Leliveld AM, Goossens-Laan CA, **Aben KK**, Özdemir BC. Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. *World J Urol*. 2022 Jul 1. doi: 10.1007/s00345-022-04080-6. Online ahead of print. Impactfactor: 3,661

Ripping TM, Rammant E, Witjes JA, Aaronson NK, van Hemelrijck M, **van Hoogstraten LM**; BlaZIB study group, Kiemeny LA, **Aben KK**. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. *Health Qual Life Outcomes*. 2022 Dec 29;20(1):171. doi: 10.1186/s12955-022-02064-z. Impactfactor: 3,077

Roy P, van Peer SE, de Witte MM, Tytgat GA, **Karim-Kos HE**, van Grotel M, van de Ven CP, Mavinkurve-Groothuis AM, Merks JH, Kuiper RP, Hol JA, Janssens GO, de Krijger RR, Jongmans MC, Drost J, van der Steeg AF, Littooij AS, Wijnen MH, van Tinteren H, van den Heuvel-Eibrink MM. *Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year's experience of national centralization*. PLoS One. 2022 Jan 13;17(1):e0261729. doi: 10.1371/journal.pone.0261729. eCollection 2022.

Impactfactor: 3,752

Schulpen M, Roy P, Wijnen MH, Tytgat GA, van den Heuvel-Eibrink MM, van Tinteren H, **Karim-Kos HE**. *Incidence and survival of paediatric renal tumours in the Netherlands between 1990 and 2014*. Eur J Cancer. 2022 Sep 26;175:282-290. doi: 10.1016/j.ejca.2022.08.021. Online ahead of print.

Impactfactor: 10,002

Steenard RV, Kerkhofs TM, **Zijstra M**, **Mols F**, Kerstens MN, Timmers HJ, van Leeuwen RS, Dreijerink KM, Eekhoff EM, Nieveen van Dijkum EJ, Corssmit EP, Kapiteijn E, Kremers MN, Feelders RA, Haak HR. *Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry*. Cancers (Basel). 2022 Mar 8;14(6):1366. doi: 10.3390/cancers14061366.

Impactfactor: 6,575

van den Bergh GP, Kuppen MC, Westgeest HM, Mehra N, Gerritsen WR, **Aben KK**, van Oort IM, van Moorselaar RJ, Somford DM, van den Eertwegh AJ, Bergman AM, van den Bergh AC, Uyl-de Groot CA. *Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry*. Prostate Cancer Prostatic Dis. 2022 Oct 12. doi: 10.1038/s41391-022-00605-7. Online ahead of print.

Impactfactor: 5,455

van Ginkel N, Hermans T, Meijer D, Boormans J, Voortman J, Mertens I, van Beek S, Vis A; the Dutch Cystectomy Snapshot Research Group (**Aben KK**). *Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study*. Int. Uro. And Nephrol. 2022 54, 3145–3152.

Impactfactor: 2,266

van Hoogstraten LM, Witjes JA, Meijer RP, Ripping TM; BlaZIB study group, Kiemeney LA, **Aben KK**. *Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent*. BJU Int. 2022 Jan 22. doi: 10.1111/bju.15697. Online ahead of print.

Impactfactor: 5,969

van Hoogstraten, LM, Kiemeney, LA, Meijer, RP, van Leenders, GJ, Vanneste, BG, Incrocci, L, Smilde, TJ, **Siesling, S**, Witjes, JA, **Aben, KK**; on behalf of the BlaZIB study group and the COVID and Cancer-NL consortium. *The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands*. Bladder Cancer, 2022 Jun; vol. 8, no. 2, pp. 139-154.

Impactfactor: 1,449

Vernooij RW, Cremers RG, Jansen H, Somford DM, Kiemeney LA, van Andel G, Wijsman BP, Busstra MB, van Moorselaar RJ, Wijnen EM, Pos FJ, Hulshof MC, Hamberg P, van den Berkmortel F, Hulsbergen-van de Kaa CA, van Leenders GJ, F Utterer JJ, van Oort IM, **Aben KK**. *Corrigendum to "Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study"*. Urol Oncol. 2022 May 30;S1078-1439(22)00177-6. doi: 10.1016/j.urolonc.2022.05.007. Online ahead of print.

Impactfactor: 2,954

Vromans RD, Tillier CN, Pauws SC, van der Poel HG, **van de Poll-Franse LV**, Krahmer EJ. *Communication, perception, and use of personalized side-effect risks in prostate cancer treatment-decision making: an observational and interview study*. Patient Educ Couns. 2022 May 4;S0738-3991(22)00211-7. doi: 10.1016/j.pec.2022.04.017. Online ahead of print.

Impactfactor: 3,467

Walraven JE, Ripping TM, Oddens JR, van Rhijn BW, Goossens-Laan CA, Hulshof MC; BlaZIB study group, Kiemeney LA, Witjes JA, **Lemmens VE, van der Hoeven JJ**, Desar IME, **Aben KK, Verhoeven RH**. The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer. *BJU Int.* 2022 Jul 21. doi: 10.1111/bju.15856. Online ahead of print. Impactfactor: 5,969

Wollersheim BM, van der Poel HG, van Asselt KM, Pos FJ, Tillier CN, Akdemir E, Vis AN, Lampe MI, van den Bergh R, Somford DM, Knipscheer B, Cauberg EC, Noordzij A, Aaronson NK, Boekhout AH, **van de Poll-Franse LV**. Quality of early prostate cancer follow-up care from the patients' perspective. *Support Care Cancer.* 2022 Oct 28. doi: 10.1007/s00520-022-07396-6. Online ahead of print. Impactfactor: 3,359

Wollersheim BM, van Asselt KM, Pos FJ, Akdemir E, Crouse S, van der Poel HG, Aaronson NK, **van de Poll-Franse LV**, Boekhout AH. Specialist versus Primary Care Prostate Cancer Follow-Up: A Process Evaluation of a Randomized Controlled Trial. *Cancers (Basel).* 2022 Jun 28;14(13):3166. doi: 10.3390/cancers14133166. Impactfactor: 6,575

13.2 Overige publicaties

Deukeren DV, **Heesterman BL**, Roelofs L, Kiemeney LA, Witjes JA, Smilde TJ, Leenders GJ, Incrocci L, Vanneste BG, Meijer RP, **Siesling S**, Bezooijen BP, **Aben KK**; COVID and Cancer-NL consortium. Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. *Cancer Treat Res Commun.* 2022 Apr 2;31:100553. doi: 10.1016/j.ctarc.2022.100553. Online ahead of print.

B1 Impactfactoren tijdschriften

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Oncologica	4,311	4
American Journal of Hospice and Palliative Medicine	2,090	1
Annals of Oncology	51,769	2
Annals of Surgical Oncology	4,339	4
Annals of Surgery	13,787	1
AOGS Acta Obstetrica et Gynecologica Scandinavica	4,544	1
BJC British Journal of Cancer	9,082	2
BJD British Journal of Dermatology	11,113	2
BJH British Journal of Haematology	8,615	2
BJS British Journal of Surgery	11,782	3
BJS Open	3,875	1
BJU International	5,969	2
Bladder Cancer	1,449	1
Blood	25,669	1
Blood Advances	7,642	1
Blood Cancer Journal	9,812	4
BMC Cancer	4,638	3
BMC Health Services Research	2,908	2
BMC Medical Education	3,263	1
BMC Medical Informatics and Decision Making	3,298	2
BMC Medical Research Methodology	4,614	2
BMC Palliative Care	3,113	1
BMJ Open	3,007	3
Breast Cancer Research	8,408	3
Breast Cancer Research and Treatment	4,624	6
British Medical Bulletin	5,841	1
Cancer	6,921	2
Cancer Communications	15,283	1
Cancer Epidemiology	2,89	2
Cancer Epidemiology, Biomarkers & Prevention	4,090	1
Cancer Medicine	4,711	3
Cancer Science	6,518	1
Cancers (Basel)	6,575	14
Clinical Colorectal Cancer	4,035	4
Clinical Endocrinology	3,523	1
Clinical Gastroenterology and Hepatology	13,576	1
Clinical Genitourinary Cancer	3,121	1
Clinical Lung Cancer	4,84	1
Clinical Nutrition	7,643	1
Critical Reviews in Oncology/Hematology	6,625	2
Ctro Clinical and Translational Radiation Oncology	4,739	1
Current Oncology	3,109	2

Disability and Rehabilitation	2,439	2
Diseases of the esophagus	2,822	1
eClinicalMedicine	17,033	1
EJC European Journal of Cancer	10,002	14
EJSO European Journal of Surgical Oncology	4,037	4
ESC Heart Failure	3,612	1
ESMO Open cancer horizons	6,883	2
European Journal of Cancer Care (Engl.)	2,328	10
European Journal of Cancer Prevention	2,164	1
European Journal of Cardio-Thoracic Surgery	4,534	1
European Journal of Human Genetics	5,351	2
European Journal of Oncology Nursing	2,588	1
European Radiology	7,034	1
European Urology	24,344	1
Frontiers in Oncology	5,738	4
Gynecologic Oncology	5,304	3
Haematologica	11,049	2
Head & Neck	3,821	1
Health and quality of life outcomes	3,077	1
Hemasphere	8,3	2
Histopathology	7,778	1
HPB	3,842	3
IJC International Journal of Cancer	7,316	6
International Journal for Quality in Health Care	2,257	1
International Journal of Colorectal Disease	2,796	2
International Journal of Epidemiology	9,685	1
International Journal of General Medicine	2,145	1
International Journal of Gynecological Cancer	4,661	1
International Journal of Gynecology & Obstetrics	4,447	1
International Urogynecology Journal	1,932	1
International Urology and Nephrology	2,266	1
JAAD Journal of the American Academy of Dermatology	15,487	1
JCO Journal of clinical oncology	50,739	2
JID Journal of Investigative Dermatology	7,59	2
JNCCN Journal of the nat. comprehensive cancer network	12,693	1
JNCI Journal of the National Cancer Institute	11,816	2
Journal of Bone Oncology	4,491	1
Journal of Cancer Research and clinical oncology	4,322	1
Journal of Cancer Survivorship	4,062	6
Journal of Clinical Epidemiology	7,407	3
Journal of Clinical Nursing	4,423	1
Journal of Health Psychology	3,789	1
Journal of Neuro-Oncology	4,506	2
Journal of Orthopaedic Research	3,103	1
Journal of Palliative Medicine	2,947	1
Journal of the European Academy of Dermatology and Ven.	9,228	1
Leukemia	12,897	2
Leukemia & lymphoma	2,996	2
Lung Cancer	6,081	2

Nature Communications	17,694	1
Nature Medicine	87,244	1
Neuro Oncology	13,029	3
NeuroImage: Clinical	4,891	1
Nutrition and cancer	2,816	1
Otolaryngology–Head and Neck Surgery	5,591	1
Palliative medicine	5,713	1
Palliative supportive care	3,733	1
Patient Education and Counseling	3,467	1
Plos One	3,752	4
Preventive Medicine	4,637	1
Prostate Cancer and prostatic diseases	5,455	2
Psychology and Health	3,358	1
Psycho-Oncology	3,955	2
Radiation Oncology	4,309	1
Radiotherapy & Oncology	6,901	5
Scientific Reports	4,997	2
Supportive Care in Cancer	3,359	15
Surgical Endoscopy and other interventional techniques	3,453	1
TAU Translational Andrology and Urology	2,479	1
The Breast	4,254	3
Therapeutic advances in medical oncology	5,485	3
The Lancet Child & Adolescent Health	37,746	1
The Lancet Gastroenterology & Hepatology	45,042	1
The Lancet Oncology	54,433	6
The Oncologist	5,837	1
Thorax	9,203	2
Trials	2,728	1
Urologic Oncology: Seminars and Original Investigations	2,954	1
Value in health	5,156	2
World Journal of Urology	3,661	1

Tabel 2 Overzicht tijdschriften zonder impactfactor

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
Cancer Treatment and Research Communications	1
Clinical Nutrition Open Science	2
ejHAEM	1
Endoscopy International Open	1
F1000Research	1
JMIR Aging	1
JMIR Cancer	3
Journal of patient-reported outcomes	1
Neuro-oncology Advances	1
Research Involvement and Engagement	1
Studies in Health Technology and Informatics	1
The Lancet Regional Health Europe	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

